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ABSTRACT 
 
COURTNEY G WOODS: Role of Nuclear Receptor–Independent Pathways in the  
Mechanism of Action of Peroxisome Proliferators 
(Under the direction of Dr. Ivan Rusyn) 
 
Peroxisome proliferators are a structurally diverse group of chemicals that are non-genotoxic 
hepatocarcinogens in rodents. For decades there has been controversy surrounding these 
compounds because of the uncertainty of human risk, high potential for exposure and 
insufficient understanding of their mechanism of action in rodents. Two key molecular 
pathways are thought to be important in the mode of action: activation of the nuclear receptor 
PPARα in liver parenchymal cells, and activation of Kupffer cells, which do not express 
PPARα. In hepatocytes, PPARα mediates peroxisome induction, increased fatty acid 
metabolism and alterations in gene expression. Furthermore, activation of the PPARα is 
required for peroxisome proliferator-induced carcinogenesis. In Kupffer cells, acute 
administration of peroxisome proliferators stimulates oxidant production and mitogenic 
cytokine release, as well as activation of NFκB, a transcription factor implicated in cell 
proliferation and apoptosis. The role that Kupffer cells play in chronic effects of peroxisome 
proliferators is not yet known. We hypothesized that peroxisome proliferators activate 
Kupffer cells to produce oxidants that may be involved in oxidative cellular damage, and that 
mediate cytokine production. The cytokines stimulate proliferative and anti-apoptotic effects 
of these chemical agents. To test this hypothesis, we first evaluated whether peroxisome 
proliferators cause a sustained increase in reactive oxygen species (ROS) in rodent liver. In
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vivo measurements of ROS in PPARα -null or NADPH oxidase-deficient (p47phox-null) mice 
following sub-acute treatment with  di-(2-ethylhexyl) phthalate (DEHP) or 4-chloro-6-(2,3-
xylidino)-2-pyrimidinylthio acetic acid (WY-14,643), both model peroxisome proliferators 
revealed a persistent elevation in oxidant production with parenchymal cells, not Kupffer 
cells as the primary molecular source. Next, the role of Kupffer cell oxidants and PPARα in 
mediating proliferative, apoptotic and oxidative stress responses was assessed. Findings from 
a five month WY-14,643 feeding study suggest that NADPH oxidase is not required for 
increased hepatocellularl proliferation or DNA damage, but may be important to anti-
apoptotic effects. Finally, gene expression profiling revealed a temporal shift from Kupffer 
cell to PPARα-dependence of peroxisome proliferator-induced changes. Collectively, our 
findings demonstrate that Kupffer cell-mediated events play an important role in early 
responses, but are short-lived and likely not required for chronic effects of peroxisome 
proliferators, including hepatocarcinogenesis.  
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INTRODUCTION 
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A. PEROXISOME PROLIFERATORS  
1. General Use, Exposure and Risk Assessment 
Peroxisome proliferators are a structurally diverse group of chemicals that have been 
identified as non-genotoxic hepatocarcinogens in rodents. Members of this class, include 
naturally occurring steroids, such as leukotriene B4 (LTB4), and 8(S)- 
hydroxyeicosatetraenoic acid (8(S)-HETE), fatty acids, such as ω-3 polyunsaturated fatty 
acids, very long chain fatty acids, as well as synthetic compounds, such as hypolipidemic 
drugs (fibrates), industrial plasticizers, such as di-(2-ethylhexyl)phthalate (DEHP), some 
pesticides, and halogenated solvent, trichloroethylene (TCE) [1]. Within the peroxisome 
proliferator class, phthalate esters are one of the most important chemical groups. The 
widespread use of phthalates in consumer products, medical devices, food packaging, 
automotives and other applications has greatly increased the potential for occupational and 
environmental exposure. Common exposure routes for the general population include 
inhalation, ingestion, intravenous and dermal contact [2]. Children, blood-transfusion 
patients and dialysis patients represent two segments of the population at high risk of 
exposure, due to the use of phthalates in children’s toys and medical tubing and containers. 
Intravenous exposure levels in patients can range from 1-2 mg/kg/day and infants may ingest 
10-100 µg /kg/ day from chewing on toys containing phthalates [3].  In 2005, the European 
Union approved a permanent ban (to update the temporary ban issued in 1999) on use of 
phthalates in children’s toys.  The US currently does not restrict its use in any products.  
In 2000, the International Agency for Research on Cancer (IARC) downgraded 
DEHP to a category reserved for chemicals with no evidence of cancer causing potential in 
humans on the basis that “the mechanism (peroxisome proliferation) by which DEHP 
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increases the incidence of hepatocellular tumours (sic) in rats and mice is not relevant to 
humans” [4]. Several other peroxisome proliferators, including clofibrate, and gemfibrozil 
are also categorized by IARC in Group 3, as not classifiable with regard to human 
carcinogenicity. The US Environmental Protection Agency (US EPA) classifies the DEHP 
and other phthalate esters as a probable carcinogen, with the qualifier that there is inadequate 
data to provide a causal link between human exposure and cancer.   
 The dearth of epidemiological data and unknown human relevance of mechanisms of 
action of peroxisome proliferators in laboratory animals makes it challenging to determine 
human risk of cancer by phthalates and other peroxisome proliferators. A limited amount of 
human data from long term, large scale studies investigating the effects of peroxisome 
proliferators is available. The few epidemiological studies that have been conducted failed to 
observe a correlation between peroxisome proliferator exposure and cancer incidence [5-7]. 
In addition to gathering human data, there remains a considerable amount of work to be done 
in the way of elucidating the mechanism of carcinogenesis in rodents and understanding the 
relevance of animal data to human risk.    
       
2. Pathophysiological changes and carcinogenesis in rodent liver following peroxisome 
    proliferator treatment 
Many of the effects of peroxisome proliferators are mediated by nuclear receptor 
peroxisome proliferator activated receptor (PPAR)α.  Ligand binding of PPARα by 
peroxisome proliferator compounds leads to transcriptional activation of genes encoding 
peroxisomal enzymes [8].  Peroxisome proliferators, as the name implies, also cause a 
marked increase in the number and size of peroxisomes [9]. Peroxisomes are ubiquitous 
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organelles that are largely responsible for fatty acid β-oxidation of very long chain fatty 
acids, oxidation of cholesterol derivatives, D- and L- amino acid oxidation, and purine 
catabolism. In rat liver, an array of H2O2 -generating oxidases are present in peroxisomes, 
including urate oxidase, acyl-coA oxidase (ACO), along with H2O2-degrading enzyme 
catalase. While peroxisome proliferation and induction of fatty acid metabolism are 
hallmarks of peroxisome proliferator treatment, a causal link between this response and 
tumor formation has yet to be identified [10]. 
Exposure to peroxisome proliferators causes a range of acute and chronic pleiotropic 
responses in rodent liver. Gross and histological hepatic changes observed following 
treatment with peroxisome proliferators include hepatomegaly, hepatocellular hyperplasia 
and hypertrophy [11]. Peroxisome proliferators also cause a significant reduction in adiposity 
and lower serum triglyceride levels, a characteristic for which it has been exploited as a 
therapeutic agent for hyperlipidemic patients. Lipid lowering effects of perioxisome 
proliferator pharmaceutical compounds are a result of increased lipid metabolism and 
transport [12]. Peroxisome proliferators also contribute to increased oxidant production in 
cells through induction of peroxisomal, mitochondrial and microsomal and enzymes, and 
reduction in glutathione S-transferase and superoxide dismutase [13-15].  
Chronic exposure to peroxisome proliferators in rodents leads to the formation of 
hepatocellular neoplasia. The tumors are generally multiple in liver and have been known to 
metastasize to the lungs. Nafenopin was the first peroxisome proliferators proven to cause 
hepatocellular carcinomas in mice [16]. Subsequently, WY-14,643 and DEHP were shown to 
induce liver tumors in rats and mice [17,18].  Potent peroxisome proliferators such as 
ciprofibrate, WY-14643 and tibric acid induced liver tumors in 100% of the rats and mice 
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that were given dietary treatment for 50-60 weeks [19].  Less potent peroxisome proliferator, 
DEHP requires at least 70 weeks for tumor development [17]. Interestingly, studies have 
shown that most of the effects of peroxisome proliferators are reversible [20]. Even 
adenomas can regress when peroxisome proliferator administration ceases. As stated 
previously, PPARα-null mice are resistant to peroxisome proliferator-induced tumorigenesis 
[21]. Surprisingly, naïve acyl-coA oxidase null mice have been shown to develop 
spontaneous tumors [22].  
 Peroxisome proliferator-induced tumors histologically can be trabecular to poorly 
differentiated in appearance. These tumors do not express the classical liver markers gamma-
glutamyltranpeptidase (GGT) or glutathione-S-transferase (GST-π) [23,24]. Protein profiling 
confirmed reduction of, GST-π, which suggests that PPARα may be a negative regulator of 
this enzyme [25]. 
3. Species Differences in response to peroxisome proliferators 
Across species, there is a significant difference in response to peroxisome 
proliferators. While mice and rats appear to be a very susceptible species, with long-term 
peroxisome proliferator administration resulting in liver carcinomas and adenomas, there is 
no evidence to date that chronic administration of these agents leads to tumors in non-human 
primates or humans [11]. In fact, humans, and non-human primates appear to be refractory to 
many of the pleiotropic responses associated with these compounds, including hepatoceulluar 
and hepatic peroxisome proliferation for many peroxisome proliferator compounds.  
Gemfibrozil, fenofibrate and nafenopin cause hepatic peroxisomal proliferation and 
significant induction of peroxisomal enzymes is rodents, but cause only a slight increase or 
no change in enzyme activity or peroxisome abundance in the non-human primates and dogs. 
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Conversely, potent peroxisome proliferator ciprofibrate has been shown to increase 
peroxisome number and activity in marmosets and rhesus monkeys [26,26]. In vitro studies 
have demonstrated that cell proliferation has been identified as a correlative marker of 
species sensititivy to peroxisome proliferators, over anti-apoptotic effects [27]. 
 Expression of PPARα is at least 10–fold less in humans than in rodents [28]. It is 
possible that the low level of PPARα expression in humans is sufficient to mediate 
peroxisome proliferator-induced hypolipidemia, but not adequate to activate the numerous 
genes associated with rodent peroxisome proliferation and cancer. In addition to differences 
in expression, there also appears to be a difference in the genes regulated by rodent PPARα 
and human PPARα. In vitro experiments have shown that genes responsive to PPARα in 
rodent liver were not responsive in human liver cell lines, even when human PPARα was 
overexpressed [29,30]. The comparison between rodent and human peroxisome proliferators 
response element (PPRE) sensitivity/responsiveness have also been made. It has been shown 
that acyl-coA oxidase in rats responds to peroxisome proliferators via its PPRE, whereas the 
human acyl-coA oxidase fails to respond because its PPRE is inactive [31]. Finally, species 
differences in metabolism are also being investigated. A study investigated enzyme activity 
in DEHP-treated microsomes from rats, mice and marmoset  [32]. The most prominent 
species differences were most evident in lipase activity, the enzyme responsible for 
converting DEHP to mono (2-ethylhexyl) phthalate (MEHP). A 150 to 350-fold difference 
was observed with mice exhibiting the highest activity and marmosets exhibiting the lowest.  
To help determine susceptibility of humans to peroxisome proliferators, determining which 
molecular events are important for rodent carcinogenicity of these agents is necessary.  
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B. KEY EVENTS IN THE MODE OF ACTION OF PEROXISOME 
PROLIFERATORS AND THE MOLECULAR MEDIATORS INVOLVED  
1. Induction of peroxisomal proliferation by peroxisome proliferators 
Induction of peroxisomes is thought to be important in the mode of action of 
peroxisome proliferators because of their role in mediating oxidative stress which may be 
responsible for DNA damage and altered cell turnover. While PPARα activation is 
responsible for transcriptional regulation of peroxisomal genes, evidence for PPARα-
independent peroxisome proliferation by WY-14,643 and fenofibrate exists [33,34]. In fact, 
compounds with high specificity for PPARγ over PPARα display a high degree of 
peroxisome proliferation (DeLuca et al., 2000). These findings suggest that cross-talk 
between PPAR isoforms may occur and contribute to peroxisome proliferation and some of 
the pleiotropic effects of peroxisome proliferation. Though the weight of evidence for 
peroxisome proliferation by peroxisome proliferators is very strong, there is uncertainty of a 
causal link to cell proliferation and tumor formation. Previous studies have shown a poor 
correlation between peroxisome proliferation and hepatocellular proliferation (Marsman et 
al., 1988).  
 
2. Increased cell proliferation and suppression of apoptosis by peroxisome proliferators 
Induction of cell proliferation is an important event in the mode of action of 
nongenotoxic carcinogens. Increased cell replication facilitates the fixation of DNA damage 
and silencing of tumor suppressor genes. These conditions promote clonal expansion of 
mutated cells and development of focal lesions in the liver. Peroxisome proliferators appear 
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to induce mitogenic, not compensatory cell proliferation [35]. Several compounds have been 
identified as possessing mitogenic properties, including nafenopin, WY-14, 643, ciprofibrate 
and clofibric acid [35-38]. Also peroxisome proliferator-induced increases in expression of 
proliferating cell nuclear antigen (PCNA), cyclin dependent kinases (CDKs), cyclins, and 
other cell cycle regulatory proteins in mouse liver have been reported [39], although the 
mechanism for this regulation remains unknown. A strong correlation between replicative 
DNA synthesis and hepatocarcinogenecity has been demonstrated using peroxisome 
proliferators, DEHP and WY-14,643. Cell replication, which varies greatly between DEHP 
and WY-14,643 was the better determinant of the two compound’s tumorigenic potency, than 
peroxisomal proliferation, which is comparable between both compounds [38]. This and 
other studies also demonstrated a rapid induction of cell proliferation, within several hours of 
treatment. Despite continued treatment, the proliferative response was diminished to control 
levels for DEHP and slightly above control for WY-14,643 by 4 weeks of treatment. These 
findings point to the importance of cell proliferation in the carcinogenic mechanism of these 
compounds. 
Suppression of apoptosis is another important cellular event that contributes to non-
genotoxic carcinogenesis. Just as cell proliferation is critical to clonal expansion of initiated 
cells, apoptosis is equally as important in removing DNA-damaged cells that could 
potentially be tumorigenic. Viability assays have shown that peroxisome proliferator-treated 
rat hepatocytes can be maintained for at least 4 weeks, compared to 8 days for control-treated 
cells. Also signs of apoptosis (i.e. condensed or fragmented nuclei) were less frequently 
observed in peroxisome proliferator-treated cultures [40]. A role for tumor necrosis factor 
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(TNF)α in anti-apoptotic effects of peroxisome proliferators has been previously 
demonstrated [41]. 
 
3.  Induction of oxidative stress and DNA damage by peroxisome proliferators 
Oxidative stress is another important mechanism of action of non-genotoxic 
carcinogens. Peroxisome proliferators are well known for their induction of metabolizing 
enzymes. H2O2 generation from these enzymes has been implicated an important event in the 
mechanism of action of these compounds. Peroxisomal oxidases and cytochrome P450 
(CYP) enzymes are the two main sources of H2O2 in parenchymal cells.  Under normal 
physiologic conditions they account for about 80% of the H2O2 in the liver [42]. Acyl-coA 
oxidase and the 4A family of CYPs are associated with the degradation of long chain and 
very long chain fatty acids by β-oxidation and ω-oxidation, respectively. CYP4A has also 
been identified as a primary route for metabolism of lipid peroxidation product, trans-4-
hydroxy-2-nonenal (HNE) [42,43]. Expression of CYP4A and acyl-coA oxidase enzymes 
can increase by 20- to 40-fold when induced by peroxisome proliferators, thus increasing the 
H2O2 load on the cell considerably [44,45]. Other sources of peroxisome proliferator-induced 
oxidants include Kupffer cells. These cells produce highly reactive superoxide and nitric 
oxide radicals which may be involved in second messenger signaling and/or macromolecular 
damage. Previous studies have demonstrated that NADPH oxidase in nonparenchymal cells 
is essential for early oxidant production by peroxisome proliferators [46].  
There is still uncertainty as to whether there is a significant increase in oxidant 
production by peroxisomes. The H2O2 generating enzymes are balanced with induction of 
oxidant scavenging enzymes, such as catalase [44,47]. Though the induction of catalase is 
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not proportional to that of acyl-coA oxidase, catalase has a high capacity for scavenging 
H2O2.  Furthermore, there are conflicting data regarding the level of damage inflicted upon 
macromolecules by peroxisome proliferator-induced oxidants. In parenchymal cells, 
conversion of H2O2 to reactive hydroxyl radicals (following Haber-Weiss chemistry) that 
immediately react with surrounding lipid membranes is one hypothesized mechanism of 
intra-hepatic oxidative stress. Lipid radicals and other by-products of peroxidation can cause 
oxidative damage to DNA. Several studies have reported increases in lipid peroxidation 
products such as conjugated dienes, aldehydes, and HNE as a result of peroxisome 
proliferators treatment in rats [48,49]. However, there are an equal number of studies that 
have failed to detect any increases. F2-isoprostanes, a sensitive marker of arachidonic acid 
peroxidation were not significantly elevated in WY-14,643 treated mice. These experiments 
were however conducted relatively low dose of WY-14,643 (100 ppm) [50], which may have 
been insufficient for inducing oxidative damage. Oxidation of DNA bases, resulting in 
formation of 8-hydroxy deoxyguanosine (8-OHdG) has also been detected in livers of rats 
chronically exposed to peroxisome proliferators [51,52]. These adducts, if unrepaired, can be 
fixed into gene mutations during DNA replication. Other studies in rats have either failed to 
demonstrate increases in 8-OHdG in treated versus control liver DNA, or have been unable 
to link the magnitude of 8-OHdG levels to tumor multiplicity [53,54]. 
 With regards to peroxisome proliferator –mediated changes in cell turnover, a great 
deal of uncertainty in the role of reactive oxygen species still exists. Oxidants (produced in 
parenchymal and nonparenchymal cells) are thought to act as signaling molecules to recruit 
mitogenic cytokines which cause increased cell turnover.  
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4. PPARα as a mediator of lipid metabolism and peroxisome proliferator-induced 
hepatocarcinogenesis 
PPARα is a transcription factor involved in regulating expression of genes, largely 
involved in fatty acid metabolism (Figure 1.1). PPARα activation by peroxisome 
proliferators leads to transcription of genes that encode proteins involved in fatty acid 
metabolism and transport. Enzymes such as peroxisomal acyl-coA oxidase are increased 15-
fold or greater in liver tissue that exhibits peroxisome proliferation [19,47]. Also ω-oxidation 
enzyme activity (i.e. CYP4A superfamily) is significantly elevated by PPARα agonists 
[55,56]. It is suspected that PPARα-mediated induction of lipid metabolism and reverse 
transport of cholesterol is what contributes to a reduction in serum cholesterol and 
triglyceride levels resulting from PPARα adminstration [12].  PPARα-null mice exhibit 
significantly higher serum lipid levels than their wild type counterparts and are refractory 
from peroxisome prolierator-induced reductions in serum lipids [57]. Indeed, the role of 
PPARα in transcriptional activation of many mediators in fatty acid metabolism clearly 
points to its importance physiologically in lipid homeostasis. The relevance of peroxisome 
proliferation and induction of lipid metabolism to the mechanism of carcinogenesis, however 
is still unknown. Metabolizing enzymes are an important source of oxidants which may be 
involved in mediating the effects of peroxisome proliferators (i.e through signaling) and may 
be involved in oxidative DNA, protein or lipid damage.   
Activation of PPARα is required for peroxisome proliferator-induced tumorigenesis 
[21]. An 11-month WY-14,643 feeding study resulted in hepatocellular adenomas or 
carcinoma development in all wild type mice, while PPARα-null mice given the same 
treatment did not develop tumors, nor did they exhibit any of the pleiotropic responses 
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associated with peroxisome proliferator treatment. Though the mechanism of carcinogenesis 
is still largely unknown, this single study demonstrates the importance of PPARα in 
mediating the carcinogenicity by peroxisome prolifertators. Studies where PPARα wild type 
and knockout mice were fed different PPARα agonists have shown similar results [58].    
PPARα activation and perturbation of cell proliferation and apoptosis are all causally 
linked to peroxisome proliferator-induced liver carcinogenesis, but the molecular 
mechanisms by which these events occur and how PPARα is involved remains to be shown. 
DNA replication and proliferation in hepatocytes are PPARα dependent, though there is no 
evidence of direct transcriptional regulation on cell-cycle genes by PPARα. It is clear that 
cyclin and CDK expression is elevated by PPARα agonists [39], but these genes do not 
possess a PPRE. It has been suggested that these mRNA are indirectly regulated by PPARα 
and more directly regulated by PPARα specific target genes. Previous studies have shown 
that PPARα is critical for cytokine-induced cell proliferation through mediating Ras and 
RhoA prenylation [59]. One hypothesis is that activation of PPARα results in the formation 
of various by-products of lipid metabolism, which facilitate membrane binding of small 
GTPases (i.e. Ras, RhoA). Once membrane-bound, these GTPases can stimulate cell 
proliferation in response to mitogenic signals.  
PPARα also appears to play a role in inhibiting apoptosis. In vitro studies with WY-
14,643, nafenopin and methylclofenapate showed suppression of spontaneous hepatocyte 
apoptosis and TGFβ1-induced apoptosis with peroxisome proliferators administration 
[60,61]. One study shows that the inhibition of apoptosis by PPARα can be eliminated by 
introducing a negative effector regulator of the nuclear receptor [62]. 
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5. Role of Kupffer cells in pleiotropic effects of peroxisome proliferators 
In vitro studies using peroxisome proliferators in pure hepatocytes fail to replicate the 
proliferative reponses observed in vivo [38]. This observation led to the hypothesis that 
nonparenchymal cells may be involved in peroxisome proliferator-induced cell replication. 
While the importance of PPARα in peroxisome proliferator-induced carcinogenesis is 
undisputable, many studies have revealed PPARα-independent responses in rodent liver that 
may be just as important. The role of Kupffer cells in peroxisome proliferator-induced 
responses has been studied extensively over the last 10 years. 
When activated, Kupffer cells, which are the resident macrophages of the liver release 
mitogenic cytokines and chemotactic mediators (e.g. tumor necrosis factor-alpha epidermal 
growth factor, hepatocyte growth factor) which can influence cell growth. Both in vitro and 
in vivo experiments demonstrate that peroxisome proliferators are capable of activation 
Kupffer cells [63]. This activation is independent of PPARα, as  Kupffer cells do not express 
this isoform of the PPAR [64]. While a putative mechanism of Kupffer cell activation has yet 
to be determined, it is hypothesized that these compounds either diffuse into membranes due 
to their lipophilicity or peroxisome proliferators incorporate into low density lipoproteins 
(LDL) and binding of the modified lipoprotein on the LDL receptors causes activation of 
Kupffer cells.  
Kupffer cell inhibitors have been used extensively to demonstrate the role of 
nonparenchymal cells in cell proliferation. WY-14,643–induced increases in hepatocyte 
proliferation were abrogated by inactivating Kupffer cells with methyl palmitate or glycine 
[65,66]. Increases in mRNA expression of mitogenic cytokine, TNFα were also blocked. 
These findings point to the importance of Kupffer cells in hepatocyte growth and also 
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implicate TNFα as a mediator of cell proliferation. The importance of TNFα to peroxisome 
proliferator-induced cell proliferation was proven when WY-14,643-induced increases in cell 
turnover were completely blocked by pre-treatment with anti- TNFα antibodies [67]. It 
should be noted that peroxisome proliferators induce levels of TNFα production by Kupffer 
cells that are well below levels necessary to cause inflammation or apoptosis, as these are not 
responses associated with peroxisome proliferator exposure [68,69]. In vitro studies 
demonstrated that absence of nonparenchymal cells prevents hepatic proliferation by WY-14, 
643 or nafenopin [70,71]. Collectively, these findings clearly demonstrate a dependence on 
Kupffer cells for proliferative responses observed following peroxisome proliferator 
treatment. More specifically, it can be concluded that there is a causal relationship between 
TNFα from nonparenchymal cells and the proliferative effect of WY-14, 643.  
NFκB is also an important mediator of cellular responses to peroxisome proliferator 
in rodent liver. This transcription factor has been shown to regulate genes involved in cell 
growth and differentiation, apoptosis and inflammation [72]. Peroxisome proliferators, WY-
14,643 and ciprofibrate can increase NFκB [73,74] DNA binding activity. Furthermore, it has 
been demonstrated that the active form of NFκB, is almost exclusively localized in 
nonparenchymal cells at levels that are 20-fold greater than in parenchymal cells following 
acute treatment with WY-14,643 [74]. NFκB has been previously demonstrated to be 
sensitive to cellular redox state in a manner such that increases in intracellular oxidants cause 
NFκB activation [75]. Therefore, oxidant production by peroxisome proliferators may play a 
role in NFκB induction. 
Like hepatocytes, a number of oxidant producing enzymes are present, including 
NAPDH oxidase, inducible nitric oxide and xanthine oxidase. Oxidants from these sources 
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can play a role in signaling and activation of downstream mediators of cell proliferation. 
Activation of NADPH oxidase and production of superoxide occurs as a result of Kupffer 
cell activation [69]. As a result, peroxisome proliferator treatment in rodents was suspected 
to cause an increase in Kupffer cell-derived oxidants.  When measured in vitro, superoxide 
production in Kupffer cells was found to be elevated in a dose-dependent manner by WY-
14,643 and DEHP metabolite, monoethylhexyl phthalate (MEHP) [76]. This response was 
inhibited when Kupffer cells were inactivated with glycine.   In vivo measurements 
unequivocally point to NADPH oxidase in Kupffer cells as being the source of early oxidants 
production caused by peroxisome proliferators. Increased levels of α-[4-Pyridyl-1-oxide] N-
tert-butylnitrone (POBN) /radical adducts were detected in rat bile by electron spin resonance 
(ESR) two hours after DEHP administration and pre-treatment with dietary glycine abrogated 
DEHP-induced free radical production [46]. Furthermore, when this study was repeated in 
NADPH oxidase deficient (p47phox –null) and PPARα-null mice, NADPH oxidase not 
PPARα was identified as the source of early oxidant production.   A link between Kupffer 
cell-derived oxidants and events leading to  hepatocellular proliferation was made when 
inhibition of NADPH oxidase with diphenyleniodonium (DPI) blocked WY-14,643-induced 
cell proliferation and NFκB activity [77]. These responses, along with TNFα mRNA 
expression were also suppressed in p47phox –null mice. 
When considered collectively, these studies provide strong evidence for the 
involvement of Kupffer cells in cell proliferation by peroxisome proliferators. In particular, 
oxidant activation of NFκB, leading to TNFα production appears to be an early response that 
may be important to the mechanism of action of these compounds. 
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C. RATIONALE AND SPECIFIC AIMS 
1. Rationale 
The mechanism of carcinogenesis by peroxisome proliferators in rodents is not 
completely understood but is hypothesized to involve the following: (i) induction of hepatic 
peroxisomes, (iI) activation of nuclear receptor PPARα and Kupffer cells, independent of 
each other, (iii) induction of oxidant generating enzymes and production of reactive oxygen 
species that can act as second messangers and cause DNA damage, (iv) release of mitogenic 
cytokines by Kupffer cells and (v) increased proliferation of hepatocytes and decreased  
apoptosis. Figure 1.2 shows a scheme with many of the key events mediated by Kupffer cells 
and parenchymal cells. A major task remains to fit these events together to understand the 
mechanism of carcinogenesis. The major premise of the specific aims below is to elucidate 
how these cellular and molecular pathways interact to bring about the changes that lead to 
cancer and in particular, whether PPARα-independent and dependent pathways are involved 
in long-term molecular changes caused by peroxisome proliferators. 
 
2. Determine the effects of peroxisome proliferators on prolonged reactive oxygen  
    species production. 
Previous in vivo measurements revealed that the peroxisome proliferator, DEHP 
caused an increase in free radical generation in liver only 2 hr after it was administered [46]. 
We hypothesize that feeding mice a DEHP- or WY-14,643-containing diet will cause a 
sustained increase in oxidants, which will correlate with the tumorigenic potency of the 
peroxisome proliferator agent. In this aim, we will further test this hypothesis by 
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investigating oxidant production over a range of time points and determining the molecular 
source of free radicals by using knockout mice. PPARα -null and NADPH oxidase –deficient 
(p47phox-null) mice and corresponding wild type mice will be fed DEHP or WY-14,643 
(0.05% w/w) for 3 days, 1 week or 3 weeks. Following administration of a spin trap, α-(4-
pyridyl-1-oxide)-N-tert-butylnitrone (POBN) bile samples will be collected and measured by 
electron spin resonance (ESR). This experimental approach is novel, as it provides direct 
evidence of radical generation, as opposed to extrapolating this data from markers of 
oxidative stress. We expect that WY-14,643 but not DEHP will have a sustained effect on 
production of oxidants for up to 3 weeks. Furthermore, we expect that NADPH oxidase will 
contribute to observed increases in oxidant production. 
  
3. Investigate PPARα-dependent and -independent mechanisms involved in peroxisome         
proliferator-induced cell proliferation, apoptosis and DNA damage 
While it is clear that Kupffer cell-derived oxidants play a critical role in the initial 
peroxisome proliferator-induced proliferation in rodent liver, little is known about the 
potential for the long-term effects of Kupffer cell activation and whether this plays a role in 
carcinogenesis. To address this important question,  we will conduct a long-term dietary 
study in p47phox-null mice, a mouse model that was used to conclusively demonstrate the role 
of NADPH oxidase in early oxidant production, mitogenic cytokine release and cell 
proliferation by peroxisome proliferator, WY-14,643 [77]. We expect that feeding WY-
14,643, not DEHP will produce a sustained oxidant generation. For this reason, we will use 
WY-14,643 to further investigate phenotypic responses to peroxisome proliferators. WY-
14,643 (0.1%)-containing diet will be administered for 1 week, 5 weeks, or 5 months to 
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p47phox-null mice, PPARα-null mice. Cell proliferation, apoptosis and oxidative DNA 
damage endpoints will be measured, as these are key events for the mode of action of rodent 
carcinogenesis. Histological changes in liver and clinical chemistry will also be assessed. 
Since Kupffer cell activation by peroxisome proliferators is PPARα-independent, 
these results will help differentiate receptor-mediated and –independent events in the 
mechanisms of hepatocarcinogenic action of peroxisome proliferators. We hypothesize that 
there will be a significant delay in proliferative effects of WY-14,643 in NADPH oxidase-
deficient mice. 
 
4. Understand the temporal role of PPARα-dependent and -independent pathways 
using gene expression profiling. 
In this aim, we will identify variations in global transcriptional activation induced by 
WY-14,643 in our two knockout models.  Because our preliminary studies suggest that there 
may be a temporal difference in the onset of Kupffer cell-mediated and PPARα-mediated 
events, we will select both acute and sub-chronic time points for these experiments. 
Computational analysis of the data will be carried out to establish common fingerprints 
characteristic of the exposure to these agents and whether these changes correlate with dose, 
time, strain and other variables.  By assessing changes in the expression of genes involved in 
regulating cell growth, apoptosis and oxidative stress, we expect to determine genes with 
dose and/or time-dependent responses and also genes that are associated with PPARα -or 
Kupffer cell-dependent pathways. Findings from microarray experiments will be confirmed 
using RT-PCR. This is a well established technique for measuring mRNA levels and often 
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used to validate microarray findings. We expect that the results of this aim will reveal 
distinguishable “signature” profiles at each condition (dose, time, knockout gene).  
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Figure 1.1. Gene network regulated by PPARα consists primarily of lipid metabolism 
modulators.  
On this and other figures, proteins involved in cell proliferation (denoted by “*” and 
highlighted yellow), apoptosis (denoted by “†” and highlighted blue) or oxidative stress 
(denoted by “‡” and highlighted red) were identified by searching for these terms in each 
proteins’ GO Biological Processes using PathStudio software. 
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Figure 1.2. Key events in the hypothesized mechanism of hepatocarcinogenesis for 
peroxisome proliferators involve both Kupffer cells and hepatocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
 
 
 
 
 
Sustained formation of POBN radical adducts in mouse liver by peroxisome 
proliferators is dependent upon PPARα, but not NADPH oxidase 
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A. ABSTRACT 
Reactive oxygen species are thought to be crucial for peroxisome proliferator-induced 
liver carcinogenesis. Free radicals have been shown to mediate the production of mitogenic 
cytokines by Kupffer cells and cause DNA damage in rodent liver. Previous in vivo 
experiments demonstrated that acute administration of the peroxisome proliferator di-(2-
ethylhexyl) phthalate (DEHP) led to an increase in production of free radicals in liver, an 
event that was dependent on Kupffer cell NADPH oxidase, but not peroxisome proliferator 
activated receptor (PPAR)α. Here, we hypothesized that continuous treatment with 
peroxisome proliferators will cause a sustained increase in free radicals in liver. Mice were 
fed diets containing either 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (WY-
14,643, 0.05% w/w), or DEHP (0.6% w/w) for up to three weeks. Using α-(4-pyridyl-1-
oxide)-N-tert-butylnitrone (POBN), liver-derived radical production was assessed in bile 
samples by measuring POBN-radical adducts using electron spin resonance. Our data 
indicate that WY-14,643 causes a sustained increase in free radicals in mouse liver and that 
this effect is greater than that of DEHP. To understand the molecular source of reactive 
oxygen species, NADPH oxidase-deficient (p47phox-null) and PPARα-null mice were 
examined after treatment with WY-14,643. No increase in radicals was observed in PPARα-
null mice that were treated with WY-14,643 for 3 weeks, while the response in p47phox-nulls 
was similar to that of wild-type mice. These results show that PPARα, not NADPH oxidase,  
is critical for a sustained increase in radical production caused by peroxisome proliferators in 
rodent liver. Therefore, peroxisome proliferator-induced radical production in Kupffer cells 
may be limited to an acute response to these compounds in mouse liver. 
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B. INTRODUCTION 
Peroxisome proliferators are a class of structurally diverse compounds that cause 
cancer in rodents by a non-genotoxic mechanism [78-80]. The high potential for human 
exposure and the known rodent carcinogenicity of these compounds has been the cause for 
intense debate for several decades regarding their potential adverse health effects in people 
[11]. The range of pleiotropic responses that these compounds induce in rodent liver includes 
increase in the size and number of peroxisomes in parenchymal cells, hepatomegaly, and 
induction of β-oxidation enzymes [38]. Considerable differences in metabolism and 
molecular changes induced by peroxisome proliferators in the liver, most predominantly the 
activation of the nuclear receptor peroxisome proliferator activated receptor (PPAR)α, have 
been identified between species [81]. In addition, PPARα-independent events that involve 
activation of Kupffer cells that involves production of reactive oxygen species have been also 
shown to occur after acute exposure to peroxisome proliferators in rodents [46]. 
Reactive oxygen species are implicated in the carcinogenesis mode of action of 
peroxisome proliferators. Oxidants have been shown to cause DNA damage, lipid 
peroxidation, and may also mediate signaling [82,83]. Within hepatocytes, these compounds 
activate transcription of genes encoding H2O2-generating enzymes, such as acyl-coA oxidase 
(ACO) and cytochrome P450 4A (CYP4A), and these events are known to be mediated by 
PPARα [42]. Studies using Kupffer cells demonstrated an increase in superoxide production 
in vitro 30 minutes after treatment with peroxisome proliferator, 4-chloro-6-(2, 3-xylidino)-2-
pyrimidinylthio acetic acid (WY-14,643) [76]. In vivo studies of peroxisome proliferator-
induced free radicals in rats using spin trap α-(4-pyridyl-1-oxide)-N-tert-butylnitrone 
(POBN) and electron spin resonance (ESR) detection reported an increase in radical adducts 
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in liver 2 hours following di-(2-ethylhexyl) phthalate (DEHP) treatment [46]. Furthermore, 
early reactive oxygen species generation as a result of DEHP administration was attributed to 
activation of NADPH oxidase in Kupffer cells, but not PPARα.  
While many studies demonstrated a role for reactive oxygen species in the acute 
effects of peroxisome proliferators, it is not known whether Kupffer cell activation plays a 
role in radical generation during the long term exposure to peroxisome proliferators, and thus 
is a potential PPARα-independent mechanism of action of these compounds. The purpose of 
this study was to determine if peroxisome proliferator-derived reactive oxygen species 
production is in fact sustained and to identify the source of free radicals. These data provide 
direct evidence demonstrating that peroxisome proliferators cause a PPARα-dependent 
prolonged elevation in free radicals in rodent liver. Our findings suggest that Kupffer cell-
derived free radical production is ephemeral and may be involved only in the acute phase of 
the response to these compounds in rodent liver.  
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C. MATERIALS AND METHODS 
Animals  
PPARα-null male mice (SV129 background; [33,84]), p47phox-null male mice 
(C57BL/6J background; [85]) and corresponding wild-type counterparts (6-8 weeks of age) 
were used in these experiments. All animals used for this study were housed in sterilized 
cages in special facilities with a 12-hr night/day cycle. Temperature and relative humidity 
were held at 22 ± 2°C and 50 ± 5 %, respectively. The UNC Division of Laboratory Animal 
Medicine maintains these animal facilities, and veterinarians were always available to ensure 
animal health. All animals were given humane care in compliance with NIH and institutional 
guidelines and studies were performed according to approved protocols. Prior to 
experiments, animals were maintained on standard lab chow diet and purified water ad 
libitum.  
 
Chemical Treatment  
DEHP, WY-14,643, 2,2’-dipyridyl, and bathocuproinedisulfonic acid were obtained 
from Aldrich (Milwaukee, WI), and α-(4-pyridyl 1-oxide)-N-tert-butylnitrone (POBN) from 
Alexis (San Diego, CA). Control animals were given NIH-07 powdered diet. Treated animals 
were given the same diet blended with either DEHP or WY-14,643 at target concentrations 
of 0.6% w/w and 0.05% w/w, respectively. Diet was administered ad libitum for 3 days, 1 
week or 3 weeks. Acutely treated mice were given one intragastric injection of either saline 
or DEHP at a dose of 1.2 g/kg.  
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Detection of Free Radicals in Bile 
Animals were anesthetized with pentobarbital (75 mg/kg) and the spin trap POBN (1 
g/kg, i.p.) was administered. The gallbladder was cannulated using a 10-cm long 
polyvinylchloride tube and bile samples were collected into Eppendorf tubes containing 50 
µl of chelating agents, bathocupoinesulfonic acid (12 mM) and 2,2’-dipyridyl (30 mM) for 2 
hrs. Bile samples were frozen immediately after collection and stored at -80°C until analyzed 
by electron spin resonance (ESR) spectroscopy. To consume endogenous ascorbic acid in 
bile which can act as reducing agent, an ascorbate oxidase spatula (Roche, Indianapolis, IN) 
was placed in the flat cell and O2 and N2 were bubbled through the sample in the flat cell for 
10 minutes and 5 minutes, respectively. ESR spectra were recorded on a Bruker EMX ESR 
spectrometer with a super high Q cavity. Instrument settings were as follows: microwave 
power, 20 mW; modulation amplitude, 1 G; conversion time, 1.3 s; time constant, 1.3 s. 
Spectra were recorded on an IBM-compatible computer interfaced with the 
spectrophotometer and were analyzed to determine hyperfine coupling constants by computer 
simulation using EPR-WinSim software [86]. Graphical display of this data represents bile 
volume-corrected spectra amplitudes (peak-to-peak). 
 
Acyl-coA Oxidase Activity and Expression 
 Acyl-coA oxidase (ACO) activity and expression are commonly used indicators of 
peroxisome induction [87].  The activity of ACO was determined by measuring 
formaldehyde, which is formed from oxidation of methanol by hydrogen peroxide. Liver 
tissue (100 mg) was homogenized in 10 volumes of 0.25 M sucrose buffer. A volume of 1.4 
ml of reaction mixture (see [65] for details) was warmed at 37°C and mixed with 100 µl of 
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homogenate. The reaction was terminated after 5 minutes by adding 40% trichloroacetic acid. 
Blanks were prepared in parallel, in which 40% trichloroacetic acid was added before 
homogenate. Samples and blanks were centrifuged to pellet protein and 1.0 ml of the 
supernatant was added to 0.4 ml of Nash reagent containing acetyl acetone, which reacts with 
formaldehyde to form diacetyl-dihydrolutidine [88]. The concentration of formaldehyde was 
measured spectrophotometrically at λ = 405 nm. Protein concentration was determined using 
the BCA protein assay [89]. 
 ACO protein expression was measured by western blot analysis. Nuclear extracts 
were prepared from liver samples obtained from mice fed control or WY-14,643-containing 
diet for 3 weeks.  Hepatic proteins (10 µg/lane) were separated on an SDS-PAGE and 
transferred to a nitrocellulose membrane. Immunodetection of ACO was performed using an 
anti-ACO polyclonal antibody (a generous gift from Dr. Janaradan Reddy, Northwestern 
University), followed by conjugation with an HRP-labeled rabbit anti-mouse secondary 
antibody.  Chemiluminescent detection of protein was employed. 
 
 Statistics 
Data are represented as mean values plus or minus the standard error for three to six animals 
per group. One-way ANOVA was used for statistical comparison with control (*). In cases in 
which more than two treatments were used, two-way ANOVA with Tukey's multiple 
comparison test was employed for statistical comparisons of between control-(*) or DEHP- 
(†) treated groups. A p value less than 0.05 was selected prior to the study to determine 
statistical differences between groups. 
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D. RESULTS 
DEHP and WY-14,643 cause a sustained increase in free radicals 
Acute treatment with DEHP has been shown to cause an increase in liver free radical 
production in vivo [46], but it has not yet been determined by direct detection methods 
whether free radical production remains elevated for longer than 2 hrs. To investigate 
whether peroxisome proliferators cause a long-term increase in free radicals, mice were fed 
either control or DEHP-containing diet for 3 weeks. In order to establish if radical species 
that are produced after continuous treatment are similar to those that form after acute 
administration of DEHP, some mice were injected with either saline or DEHP (1.2 g/kg) 
intragastrically immediately before bile collection. Figure 2.1 shows that a DEHP-induced 
increase in free radicals is observed after both acute (2 hrs) and sub-chronic (3 weeks) 
treatment with the peroxisome proliferator compound. When injected in vivo, POBN forms a 
stable radical adduct (with a t1/2 ranging from 10-15 hrs, data not shown). Thus, the rate of 
radical production is proportional to the ESR spectrum amplitude and the level of induction 
of free radical production (i.e., the amount of the radical species being produced) caused by 
treatment with DEHP is comparable at both time points (3.2- and 2.6-fold over control, 
respectively). 
Computer simulations of the ESR spectra for DEHP-induced radicals produced at 2 
hours and 3 weeks (Figure 2.1C and 2.1F, respectively) suggest that the radical species 
responsible for POBN adduct formation were similar. For both time points, the POBN-
trapped radicals produced a composite six-line spectrum. Computer simulation of radical 
adducts produced following acute DEHP treatment (Figure 2.1C) possess hyperfine coupling 
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constants of (I) aN = 15.6 G, aβH = 3.2 G and (II) aN = 15.8 G, aβH = 2.7 G, and revealed a third 
species (III) aH = 2.0 G due to the ascorbate radical (19). The relative amount of each adduct 
species was (I) 55%, (II) 35% and (III) 11%. The predominant radical species (I) appears to 
be derived from POBN/•CO2– [90], while species II likely originated from a lipid-centered 
radical [91]. Three week treatment with DEHP produces similar radical species with 
coupling constants (I) aN = 15.7 G, aβH = 3.0 G, (II) aN = 15.8 G, aβH = 2.7 G, and (III), aH = 
1.9 G derived from the same three species, POBN/•CO2– (49%), POBN/•L (41%), and the 
ascorbate radical III contributing 10%. The significant presence of formate-derived 
POBN/•CO2– radical adducts in both samples is likely caused by reactive species produced 
by oxidizing enzymes. In a Fenton-like reaction, endogenous formate is oxidized to form a 
carbon dioxide anion radical [91].  
While our data indicates that DEHP is capable of invoking production of radical 
species in both acute (2 hrs) and sub-chronic (3 weeks) studies, it has been shown that DEHP 
is a relatively weak carcinogen that fails to produce a sustained induction of proliferative 
response in rodent liver [38]. To compare the level of free radical induction by two classical 
peroxisome proliferator compounds that differ in their carcinogenic potency, mice were fed a 
diet with either DEHP (0.6% w/w), or WY-14,643 (0.05% w/w) for 3 days, 1, or 3 weeks and 
radicals in bile were measured by ESR. Both DEHP and WY-14,643 caused a time-
dependent increase in free radicals (Table 2.1 and Figure 2.2), with the latter treatment 
causing the most significant increase over control levels beginning at 1 week of treatment. 
These findings support the hypothesis that the carcinogenic potency of peroxisome 
proliferators is likely to be related to their ability to cause oxidative stress in liver [92]. 
 32
PPARα is essential to long-term reactive oxygen species production by peroxisome 
proliferators 
Earlier studies demonstrated that acute production of DEHP-induced radical species 
in rodent liver depends on Kupffer cell NADPH oxidase, but not PPARα [46]. To determine 
if long-term reactive oxygen species production is mediated by either Kupffer cell- or 
hepatocyte-related molecular events, p47phox- and PPARα- null mice (along with their 
corresponding wild-types) were treated with WY-14,643 for 3 weeks.  POBN trapped 
radicals were collected in vivo from liver using bile and quantitated using ESR. Though the 
knock-out mice used in this study were on different background strains (SV129 and 
C57BL/6J), no strain-associated differences in free radical production were observed. Both 
wild-type strains show a significant increase in radicals caused by dietary treatment with 
WY-14,643 for 3 weeks (Figure 2.3). Interestingly, induction of radical production by 
continuous treatment with WY-14,643 occurs in NADPH-oxidase deficient mice (p47phox-
null), but not in PPARα-null mice. These results clearly demonstrate that PPARα is required 
for prolonged reactive oxygen species production caused by peroxisome proliferators.  
It has been hypothesized that induction of peroxisomal oxidases by peroxisome 
proliferators is important for the mode of action of these agents since it may lead to oxidative 
damage of DNA, proteins and lipids in rodent liver [93]. To determine if induction of 
peroxisomal enzymes correlates with sustained free radical production observed in this study, 
activity of acyl-CoA oxidase (ACO) was determined in liver homogenates from wild-type 
mice fed either DEHP or WY-14,643-containing diets for up to 3 weeks. ACO is widely used 
as a marker of peroxisomal β-oxidation [42,44] and increased expression or activity is 
hallmark to peroxisome proliferators. Both DEHP and WY-14,643 cause a progressive 
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increase in ACO activity, with more potent WY causing a greater increase of almost 30-fold 
over control as early as 3 days following diet initiation (Figure 2.4). Induction of ACO by 
DEHP and WY-14,643 persists for up to three weeks.  These results corroborate that reactive 
oxygen species levels are sustained and progressively increase with the length of treatment. 
Measurements of ACO activity in liver from both knockout mouse strains revealed an 
induction in ACO in p47phox-null mice (Figure 2.5A).  No change of enzyme activity was 
observed in PPARα-null mice. ACO protein expression (Figure 2.5B) revealed a similar 
trend. When taken collectively, these results confirm that long term reactive oxygen species 
production is PPARα−dependent, and that peroxisomal enzymes are likely a primary source.    
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E. DISCUSSION 
Involvement of reactive oxygen species in the mode of action of peroxisome proliferators 
Reactive oxygen species are thought to be intimately associated with the mechanism 
of tumorigenesis by peroxisome proliferators. This assumption is based to a large degree on 
the fact that various proteins that are induced by these chemicals in liver parenchymal cells 
(peroxisomes, mitochondria and microsomes) are prone to formation of hydrogen peroxide 
and free radical species. Thus, it was hypothesized that such overproduction of oxidants 
might cause DNA damage and lead to mutations and cancer [42,93]. In addition, recent 
discoveries show that reactive oxygen species play an important signaling role in a rapid 
increase of parenchymal cell proliferation caused by peroxisome proliferators [94,94]. 
Collectively, it appears that oxidant-related molecular events are intertwined with other 
pathways activated by peroxisome proliferators in vivo in rodent liver.   
It was initially hypothesized that fatty acyl-CoA oxidase in the peroxisome is the 
enzyme responsible for oxidative stress by peroxisome proliferators [47,95]; however, mice 
lacking this protein, instead of being protected from chemically induced liver cancer, develop 
liver tumors spontaneously, possibly as a result of a hyper-activation of PPARα by 
unmetabolized lipids [22]. A number of indirect confirmations for peroxisome proliferator-
initiated increases in reactive oxygen species have been collected over past two decades; 
however, the causative relevance of some of this evidence to the carcinogenic effect of 
peroxisome proliferators has been questioned and contrasting views have been presented 
(reviewed in [96]). Therefore, we provide direct in vivo evidence for sustained production of 
oxidants after treatment with peroxisome proliferators, as well as information on whether 
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free radicals are produced by PPARα-dependent mechanisms, both of which are critical for 
understanding the mode of action of these agents. 
 
Direct evidence for peroxisome proliferator-induced sustained production of free radicals 
in rodent liver 
Despite the fact that few question a role of oxidative stress in the mechanism of 
action of these compounds, direct evidence that free radicals are produced under conditions 
of continuous exposure to peroxisome proliferators, as well as knowledge on precise 
molecular source(s) of reactive oxygen species that are involved were still lacking. It has 
been previously reported that PPARα is not required for generation of reactive oxygen 
species in mouse liver after acute exposure to peroxisome proliferators [46]. The same study 
demonstrated that Kupffer cell NADPH oxidase was the source of free radical production in 
rodent liver within hours after administration of DEHP. Thus, Kupffer cells have been 
suggested to be a potential source of free radicals in rat and mouse liver after treatment with 
peroxisome proliferators [46,97].  
In this study, we provide the first direct evidence of peroxisome proliferator-induced 
sustained free radical production in vivo in mouse liver. It appears that ability of peroxisome 
proliferators to increase radical production in mouse liver correlates with the carcinogenic 
potency. Specifically, WY-14,643, which is known to be highly tumorigenic in rodents, 
causes greater radical production than DEHP, a weaker rodent liver carcinogen.  
We also show that irrespective of the duration of treatment with peroxisome 
proliferators when the cellular source of radicals (i.e., Kupffer cell or hepatocyte) may differ 
(see below), the ultimate macromolecule-reactive species produced in mouse liver are similar 
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and consist of roughly equal amounts of •CO2– and •L. While Kupffer cell-derived radicals 
(e.g., superoxide anion) can either react directly with the surrounding lipid membrane (at low 
pHs [98]), or be converted to a hydroxyl radical that will react with lipids; in hepatocytes, 
excess peroxisomal H2O2 conversion to a reactive hydroxyl radical in the presence of iron is 
the presumed mechanism of formation of lipid peroxides [99]. While the utility of spin 
trapping with POBN for direct detection of hydroxyl radical itself is limited due to the 
instability of hydroxyl-radical adducts [100], the high reactivity of the hydroxyl radical, 
abundance of lipids in liver and the chain reaction nature of lipid peroxidation are likely to 
facilitate the formation of •L as a key terminal radical detected here by POBN.  
 Our results indicate that continuous treatment with peroxisome proliferators causes a 
time-dependent significant increase in free radicals in mouse liver. It is interesting, however, 
that the initial increase in POBN-radical adducts following acute exposure to DEHP was 
short-lived, as an appreciable increase in radical production is not observed until after 3 
weeks of treatment with DEHP and after 1 week of treatment with WY-14,643. This result 
implies that the early, Kupffer cell-mediated, effect on increased reactive oxygen species is 
not sustained and we suggest that Kupffer cell activation by peroxisome proliferators is short 
lived (see below).  
 The peroxisome proliferator-induced PPARα-dependent (see below) prolonged free 
radical production in liver, detected here by ESR, may result from several sources in the 
parenchymal cell. A number of peroxisomal (e.g., fatty acyl-CoA oxidase) and microsomal 
(e.g., 4A superfamily of cytochrome P450 enzymes) oxidases are regulated by PPARα and 
are involved in the catabolism of long chain and very long chain fatty acids by β- and ω-
oxidation, respectively. These enzyme systems are "leaking" electrons and are known to 
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generate considerable amounts of secondary reactive oxygen species even under normal 
physiologic conditions [42].  
 Disproportionately large increases in expression of hydrogen peroxide-generating 
fatty acyl-CoA oxidase, as compared to hydrogen peroxide-degrading catalase, have been 
reported following treatment with peroxisome proliferators in rodents [44,47]. However, 
given the extremely high rate at which peroxisomal catalase converts H2O2 into H2O and O2, 
it should not escape peroxisomes [101]. Furthermore, peroxisomal β-oxidation is limited by 
substrate availability. In fact, it has been shown that treatment with peroxisome proliferators 
increased H2O2 in vitro, but not in the perfused liver because fatty acid supply is rate-limiting 
in intact cells [102,103]. Indeed, the timing of the increases in free radical production 
observed in this study did not correlate with that for the induction of ACO protein level and 
activity. However, peroxisomes devoid of catalase but capable of production of H2O2 via 
beta-oxidation of fatty acyl CoA compounds or via the activity of urate oxidase have been 
observed following clofibrate treatment and massive liver regeneration [104,105]. Thus, with 
continuous peroxisome proliferator treatment, it is still possible that catalase-deficient 
peroxisomes have less capability to scavenge the increasing pool of H2O2, resulting in the 
increase in POBN-radical adducts that were detected in bile. Marked induction of CYP4A 
[45] may be another likely source of oxidants under the condition of continuous treatment 
with peroxisome proliferators. 
  An alternative explanation for lack of increase in radicals until after 1 week of 
treatment could also be related to peroxisome proliferator-induced changes in iron 
homeostasis in rodent liver. Reactive species produced at early time points (2 hours or less) 
are presumably Kupffer-cell derived radicals (e.g., superoxide anion) that would not depend 
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on availability of excess transition metals for conversion to ESR-detectable species. 
However, a sufficient level of iron in the liver is critical for conversion of non-radical 
oxidants, like H2O2, to ESR-detectable radical species. Several studies have shown that 
dietary treatment with peroxisome proliferators in rodents creates a condition of iron 
overload in liver [106-108].  An increase in hepatic iron stores is thought to be one of the 
potential reasons for chronic oxidative stress in liver by peroxisome proliferators. In fact, an 
enhancement in lipid peroxidation as a result of hepatic iron overload after treatment with 
WY-14,643 was observed recently [108]. In addition to increased intracellular pools of iron, 
altered expression of proteins responsible for iron transport from the liver to plasma (i.e., 
transferrin receptors, ferritin, and iron regulatory protein 1) has been reported [106,109].  
 
NADPH oxidase is not a source of free radicals under condition of chronic administration 
of peroxisome proliferators 
Numerous reports in the past decade have suggested that Kupffer cells are involved in 
acute peroxisome proliferator-mediated pleiotropic responses in rodent liver. It was shown 
that Kupffer cell activation by peroxisome proliferators (i) is independent of PPARα, (ii) 
involves generation of reactive oxygen species, and (iii) leads to production of mitogenic 
cytokines (reviewed in [94]). Since it was not known whether Kupffer cell-specific events 
play a role in long-term effects of peroxisome proliferators, this study determined if this cell 
type may be involved in peroxisome proliferator-induced reactive oxygen species production 
when animals are administered these compounds for up to 3 weeks. We show here that 
radical species formation still occurs in the absence of active NADPH oxidase (as observed 
in p47phox-null mice), but is PPARα-mediated. The importance of PPARα for 
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hepatocarcinogenicity of peroxisome proliferators is well known [21]. Importantly, here we 
demonstrate, by direct measurements of radical production in liver, that PPARα-dependent 
pathways are responsible for the long-term increase in oxidants after continuous treatment 
with peroxisome proliferators. This work, together with measurements of oxidative DNA 
damage under similar conditions [110], establishes a link between PPARα, free radical 
production and DNA damage, a key step in the mechanism of carcinogenesis. 
In conclusion, this study is the first to provide direct in vivo evidence that increased 
free radical production in mouse liver is sustained following dietary treatment with 
peroxisome proliferators. Despite the apparent temporal shift in the cellular source of radicals 
(from Kupffer cells to hepatocytes) as peroxisome proliferator treatment is continued, there 
appears to be no difference in the radical species that are produced. Finally, we have 
demonstrated that long term reactive oxygen species production is mediated by PPARα and 
that NADPH oxidase-derived radicals may only be important as early responses to 
peroxisome proliferators.   
 40
 
Table 2.1.  ESR spectra amplitudes for peroxisome proliferator-treated C57BL/6J mice. 
Time 
course Treatment N 
Liver Weight 
(% Body Wt.)a 
Bile 
Volume (ml)
ESR Amplitude 
(Arbitrary 
Units) 
Vol Corrected 
ESR Amplitude
(Arbitrary 
Units)a 
 Control 6 4.6 ± 0.3 0.15 ± 0.01 23.63 ± 3.47 3.39 ± 0.38 
3 days DEHP 6 5.4 ± 0.5b 0.17 ± 0.02 9.43 ± 1.34 1.57 ± 0.25 
 WY 3 6.5 ± 0.9c 0.23 ± 0.03c 8.89 ± 3.52 1.94 ± 0.56 
 Control 4 5.7 ± 0.5 0.18 ± 0.03 13.83 ± 2.16 2.96 ± 0.78 
1 week DEHP 5 7.1 ± 1.3 0.19 ± 0.04 14.62 ± 1.99 3.06 ± 0.98 
 WY 6 8.2 ± 1.0c 0.44 ± 0.08c 12.69 ± 2.49 5.48 ± 1.64b 
 Control 4 4.4 ± 0.3 0.17 ± 0.01 11.96 ± 0.72 1.99 ± 0.18 
3 weeks DEHP 6 6.3 ± 0.3b 0.19 ± 0.02 27.55 ± 1.57 5.23 ± 0.65b 
 WY 5 11.3 ± 1.1c 0.76 ± 0.08c 10.78 ± 2.00 7.62 ± 0.57c 
 
 Data is represented as mean ± SEM. 
a Bile volume was used to determine a volume corrected ESR amplitude.  
b Denotes statistically significance from Control-fed animals (p<0.05). 
c Denotes statistical significance from DEHP-treated animals (p<0.05). 
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Figure 2.1. Production of POBN radical adducts caused by peroxisome proliferators is 
sustained. 
Representative spectra and computer simulations of radical adducts in C57BL/6J mouse liver 
following DEHP treatment are shown. Bile was collected for 2 hours after POBN 
administration (i.p.). Radical adducts in bile were detected using ESR. (A) ESR spectrum of 
radical adducts detected 2 hours following i.g. treatment with saline. (B) Same as A except 
treated with DEHP (1.2 g/kg). (C) Computer simulation of spectrum in panel B. (D) ESR 
spectrum of radical adducts detected following 3 weeks of feeding of NIH-07 diet. (E) Same 
as panel D, except diet contained DEHP (0.6% w/w).  (F) Computer simulation of spectrum 
in panel E.  
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Figure 2.2. WY-14,643 causes a greater induction of POBN radical adducts in 
C57BL/6J mice. 
Mice were fed either a DEHP (0.6% w/w)-, or WY-14,643 (0.05% w/w)-containing diet for 3 
days, 1 week, or 3 weeks. Free radical adducts in bile were measured by ESR 2 hours after 
POBN (i.p.) administration. Statistical significance (p<0.05) is indicated with asterisks (*, 
different from Control; †, different from DEHP). N.D: No Data 
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Figure 2.3. Prolonged radical species production is PPARα dependent. 
PPARα-null and p47phox-null mice were fed a WY-containing diet (0.05% w/w) for 3 weeks. 
Following POBN administration, bile was collected for 2 hours. POBN radical adducts were 
detected in bile using ESR. Statistical significance (p<0.05) is indicated with an asterisk as 
compared to the data for control diet-fed animals.  
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Figure 2.4. DEHP and WY-14,643 cause a sustained increase acyl-CoA oxidase activity. 
Mice were fed either a DEHP (0.6% w/w) or WY-14,643 (0.05% w/w)-containing diet for 3 
days, 1 week, or 3 weeks. ACO activity was measured as described in the Experimental 
Procedures.  Statistical significance (p<0.05) is indicated with asterisks (*, different from 
Control; †, different from DEHP).  
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Figure 2.5. Induction of ACO correlates with peroxisome proliferator-induced radical 
production. 
PPARα-null and p47phox-null mice were fed WY-14,643 (0.05% w/w) containing diet for 3 
weeks. (A) ACO activity was measured as described in the Experimental Procedures. (B) 
ACO protein expression was measured by western blot analysis. Statistical significance 
(p<0.05) is indicated with an asterisk as compared to the data for Control-fed animals.  
 
CHAPTER III 
 
 
 
 
 
WY-14,643-induced cell proliferation and oxidative stress in mouse liver are 
independent of NADPH oxidase 
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A. ABSTRACT 
 Long term exposure of rodents to peroxisome proliferators leads to increases in 
peroxisomes, cell proliferation, oxidative damage, suppressed apoptosis, and ultimately 
results in the development of hepatic adenomas and carcinomas. Peroxisome proliferator 
activated receptor (PPAR)α was shown to be required for these pleiotropic responses; 
however, Kupffer cells, resident liver macrophages, were also identified as playing a role in 
peroxisome proliferator-induced effects, independently of PPARα. Previous studies showed 
that oxidants from NADPH oxidase mediate acute effects of peroxisome proliferators in 
rodent liver. To determine if Kupffer cell oxidants are also involved in chronic effects, 
NADPH oxidase-deficient (p47phox-null) mice were fed 4-chloro-6-(2, 3-xylidino)-2-
pyrimidinylthio acetic acid (WY-14,643)-containing diet (0.1% w/w) for 1 week, 5 weeks or 
5 months along with  Pparα-null and wild type mice. As expected, no change in liver size, 
cell replication rates or other phenotypic effects of peroxisome proliferators were observed in 
Pparα -null mice. Through 5 months of treatment, the p47phox–null and wild type mice 
exhibited peroxisome proliferator-induced adverse liver effects, along with increased 
oxidative DNA damage and increased cell proliferation, a response that is potentially 
mediated through NFκB. Suppressed apoptosis caused by WY-14,643 was dependent on both 
NADPH oxidase and PPARα. Collectively, these findings suggest that involvement of 
Kupffer cells in WY-14,643-induced parenchymal cell proliferation and oxidative stress in 
rodent liver is an acute phenomenon that is not relevant to long-term exposure, but they are 
still involved in chronic apoptotic responses. These results provide new insight for 
understanding the mode of hepatocarcinogenic action of peroxisome proliferators.  
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B. INTRODUCTION 
 Peroxisome proliferators are a class of chemically diverse compounds such as 
hypolipidemic drugs, plasticizers, industrial solvents and pesticides. Peroxisome proliferators 
cause a number of adverse cellular and molecular changes in rodent liver, including an 
increase in the number and size of peroxisomes and proliferation of hepatocytes [38]. 
Rodents also develop hepatocellular neoplasia as a result of chronic administration of 
peroxisome proliferators [18,35,111]. Most of the pleiotropic effects of these agents are 
nuclear receptor-mediated through peroxisome proliferator-activated receptor (PPAR)α. 
PPARα activation is required for peroxisome proliferator-induced growth responses and for 
liver carcinogenesis [21]. However, a number of early events in liver that are independent of 
PPARα have also been reported, including Kupffer cell activation, release of reactive oxygen 
species and production of mitogenic cytokines [66,76,77]. 
Increased oxidant generation and cell proliferation, along with suppression of 
apoptosis, are thought to be key steps in the mode of action of non-genotoxic liver 
carcinogens, including peroxisome proliferators [38,60,93]. Within hepatocytes, these 
responses facilitate the formation and fixation of oxidative DNA lesions and clonal 
expansion of mutated cells, which could predispose cells to tumor development. It is well 
known that PPARα is required for sustained growth responses to peroxisome proliferators 
[21,39]; however, the chronic PPARα-independent mediators of cellular response are poorly 
understood. Previous studies demonstrate that Kupffer cells, the resident macrophages of the 
liver, are important mediators of acute phase responses to peroxisome proliferators.  In 
particular, reactive oxygen species produced as a result of acute peroxisome proliferator 
treatment were shown to be Kupffer cell-derived using NADPH oxidase deficient (p47phox-
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null) mice [46,77]. Also, peroxisome proliferator-induced production of mitogenic cytokines 
is a result of Kupffer cell activation [66,82,112]. It has been hypothesized that mitogens, like 
tumor necrosis factor (TNF)α and interleukin (IL)-1 are important signaling molecules 
responsible for mediating cross-talk between Kupffer cells and hepatocytes that control cell 
proliferation and apoptosis. Kupffer cell inhibitors, glycine and methyl palmitate, were able 
to block acute effects of peroxisome proliferators in rodent liver [65,66]. Similar results were 
observed in rats treated with NADPH oxidase inhibitor, diphenyleneiodonium sulfate [97]. 
Furthermore, in vitro studies have shown that an absence of non-parenchymal cells prevents 
increased DNA synthesis in purified hepatocytes treated with WY-14,643 [70,71]. The 
importance of TNFα to peroxisome proliferator-induced changes in cell turnover was 
demonstrated when increased DNA synthesis and decreased apoptosis were completely 
blocked by pre-treatment with a TNFα antibody [41,67]. Furthermore, since Kupffer cells do 
not express PPARα [64] it is likely that these effects are nuclear receptor-independent. 
From previous studies, it is clear that Kupffer cells play a critical role in the early 
events in rodent liver associated with peroxisome proliferator treatment; however, whether 
the role of the Kupffer cells is sustained has yet to be established. In this study, NADPH 
oxidase-deficient mice were used to determine if Kupffer cell-derived oxidants are necessary 
for prolonged peroxisome proliferator-induced pathological changes in liver. The data show 
that NADPH oxidase is not required for chronic proliferative response or DNA damage. We 
conclude that the role that Kupffer cell oxidants play in peroxisome proliferator-induced liver 
effects is limited and may not be a contributing factor to hepatocarcinogenesis. 
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C. MATERIALS AND METHODS 
Animals and Diet 
p47phox-null male mice (C57BL/6J background; [85]), PPARα-null male mice (SV129 
background; [33]), and corresponding wild type counterparts (6-8 weeks of age at the 
beginning of treatment) were used in these experiments. All animals used for this study were 
housed in sterilized cages in a facility with a 12-hr night/day cycle. Temperature and relative 
humidity were held at 22 ± 2°C and 50 ± 5%, respectively. The UNC Division of Laboratory 
Animal Medicine maintains these animal facilities, and veterinarians were always available 
to ensure animal health. All animals were given humane care in compliance with NIH and 
institutional guidelines and studies were performed according to protocols approved by the 
appropriate institutional review board. Prior to experiments, animals were maintained on 
standard lab chow diet and purified water ad libitum. 4-Chloro-6-(2,3-xylidino)-
pyrimidynylthioacetic acid (WY-14,643) was obtained from Aldrich (Milwaukee, WI). NIH-
07 was used as the base for the pelleted diet (prepared by Harlan Teklad, Indianapolis, IN) 
containing either 0% (control), or 0.1% w/w of WY-14,643. Dietary concentration of WY-
14,643 was measured by high performance liquid chromatography after the pellets were 
made and determined to be ±18% of the target concentration. Diet was administered ad 
libitum for 1 week, 5 weeks or 5 months. Animals had free access to water throughout the 
study and the health status of the animals was monitored every other day.  
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Tissue Collection 
 Body weight was recorded on a weekly basis per cage, not for individual animals. 
Three days prior to sacrifice mice were administered bromodeoxyuridine (BrdU)-containing 
water (0.2 g/L). At sacrifice, mice were anesthetized with pentobarbital (100 mg/kg) and 
following exsanguination, livers were removed and weighed. A section from the left lateral 
lobe was fixed in 10% formalin. A section of the duodenum, which is a rapidly proliferating 
tissue, was also collected and fixed in formalin for use as a positive control in 
immunohistochemical staining and to confirm that mice received BrdU. The remaining tissue 
was placed in an eppendorf tube and snap frozen in liquid nitrogen. These samples were 
stored at -80ºC until assayed. 
 
Histopathological Evaluation 
 A quantitative method was employed to determine the severity of necrosis, steatosis 
or inflammation in mouse liver. Slightly modified from the previous method [113], the 
scoring involves overlaying a grid on a low magnification photo of the hematoxylin/eosin-
stained liver section. The necrosis index was calculated as the # of points overlapping a 
necrotic region/total number of points overlapping the liver section. The same procedure was 
followed for steatosis and inflammation indices. Grid points over portal or central veins were 
excluded from the calculation and in cases in which the entire liver section was too large to 
be captured in one photo, the average score was taken from photos of 2 or more unique 
fields.  
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BrdU Immunohistochemistry 
 Liver tissue sections were fixed in 10% formalin for 24 hours and transferred to 70% 
ethanol.  Sections were embedded in paraffin and 5 µm slices were mounted onto Probe-On 
Plus (Fisher Scientific, Pittsburgh, PA) slides. Slides were rehydrated in serial solutions of 
xylene, 100%, 95%, 70%, 50% and 30% ethanol and water.  For BrdU staining, the tissue 
was hydrolyzed in 4N HCl for 20 minutes at 37° C and permeabilized in a 0.2% pepsin/0.2N 
HCl solution for 15 min at 37° C. Immunostaining was performed with a monoclonal 
antibody against BrdU (Dako, Carpinteria, CA) diluted 1:200 in 1% BSA in PBS.  
Immunohistochemical detection was performed using a horseradish peroxidase labeled goat 
anti-mouse secondary antibody followed by staining with a 3,3'-diaminobenzidine 
chromogen solution. Slides were counterstained using hematoxylin. Image analysis was 
performed at a magnification of 200x using Bioquant Nova Prime (Bioquant Image Analysis 
Corp., Nashville, TN) software. A labeling index was calculated as the number of positively 
stained nuclei/total number of nuclei counted x 100% (at least 2000 nuclei/slide). 
 
Preparation of Protein Extracts 
 Cytosolic and nuclear protein extracts were prepared by homogenizing 50 mg of liver 
tissue in 400 µl of buffer A, which contained 10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 
0.1 mM, EGTA, 1 mM DTT and 0.5 mM PMSF, and the homogenate was placed on ice for 
15 min. After adding 25 µl of NP-40, the homogenate was centrifuged at 4°C for 30 sec at 
14,000 rpm. The supernatant was aliquoted as the cytosolic fraction. The remaining pellet 
was resuspended in 400 µl of buffer A and 25 µl of NP-40 and centrifuged at the above 
conditions. The supernatant was discarded and remaining cells were resuspended in 250 µl of 
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buffer B containing 20 mM HEPES, 0.4 M NaCl, 10 mM KCl, 1 mM EDTA, 1 mM EGTA , 
1 mM DTT, 0.5 mM PMSF and 1 mM NA3VO4 for 30 minutes on ice. After spinning the 
mixture at 4°C for 5 min at 14,000 rpm, the supernatant was aliquoted as the nuclear fraction. 
Protein concentration of the cytsolic and nuclear extracts was determined using a BCA assay 
(Pierce Biotechnology Inc, Rockford, IL) prior to storing at 80°C.  
 
Western Blot Analysis  
To assess protein levels of Cyclin B1, Cdk1, Cdk2 and C-myc, nuclear protein 
extracts were used, while cytosolic fractions were used for measuring Caspase 8 and Caspase 
9. Proteins (10 µg/lane) were separated on a 4-12% Bis-Tris gel and transferred to a 
nitrocellulose membrane. Immunodetection was performed by incubating membranes with 
the primary antibody then conjugating with a horseradish peroxidase-labeled secondary 
antibody (Amersham, Cleveland, OH). Bands were detected using an ECL 
chemiluminescence kit (Amersham). Anti-mouse primary antibodies for Cyclin B1, Cdk1, 
Cdk4 and C-myc were from Santa Cruz Biotechnology (Santa Cruz, CA), and Cdk2 anti-
body was from Lab Vision (Fremont, CA). Antibodies for Caspase 8 and Caspase 9 were 
from Biovision (Mountain View, CA). Band intensity was quantified using Kodak 1D Image 
Analysis software (Eastman Kodak, Rochester, NY). Protein expression was normalized to 
β-actin (antibody from Abcam, Cambridge, MA). 
 
Detection of Apurinic/Apyrimidinic Sites 
Genomic DNA was extracted by a procedure slightly modified from the method 
reported previously [114]. To minimize formation of oxidative artifacts during isolation, 
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2,2,6,6-tetramethylpiperidinoxyl (20 mmol/L) was added to all solutions, and all procedures 
were performed on ice. The apurinic/apyrimidinic (AP) site assay was performed as 
previously described [115]. 
 
Electrophoretic Mobility Shift Assay 
Electrophoretic mobility shift assay (EMSA) (Panomics Inc., Redwood City, CA) 
was performed according to manufacturer’s instructions. Briefly, 10 µg of nuclear protein 
extract from liver tissue was pre-incubated with 1 µg of poly d(I-C) at room temperature.  
Binding buffer, 10 ng of DNA probe and water were added to the mixture and allowed to 
incubate for 30 minutes at 17°C. The mixture was resolved on a 6% polyacrylamide gel 
(Invitrogen Corp., Carlsbad, CA). After electrophoresis, protein was transferred to a Biodyne 
B nylon membrane (Pall Corp., East Hills, NY) then dried for 1 hour at 80°C. To reduce 
nonspecific binding, the membrane was placed in blocking buffer, followed by incubation 
with HRP-streptavidin conjugate (1:1000). The membrane was washed prior to adding ECL 
detection buffer and then exposed to film. Specificity of the NFκB probe was confirmed by 
competition assays using Hela cell nuclear extracts, whereby 2-fold excess unlabeled NFκB 
probe was added to the mixture prior to addition of labeled probe. 
 
Acyl-CoA Oxidase Activity 
 Acyl-coA oxidase (ACO) activity and expression were measured as indicators of 
peroxisomal induction [87]. The activity of ACO was determined by measuring 
formaldehyde, which is formed from oxidation of methanol by hydrogen peroxide. Liver 
tissue (100 mg) was homogenized in 10 volumes of 0.25 M sucrose buffer. A volume of 1.4 
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ml of reaction mixture (see [66] for details) was warmed at 37°C and mixed with 100 µl of 
homogenate. The reaction was terminated after 5 minutes by adding 40% trichloroacetic acid. 
Blanks were prepared in parallel, in which 40% trichloroacetic acid was added before 
homogenate. Samples and blanks were centrifuged to pellet protein and 1.0 ml of the 
supernatant was added to 0.4 ml of Nash reagent containing acetyl acetone, which reacts with 
formaldehyde to form diacetyl-dihydrolutidine [88]. The concentration of formaldehyde was 
measured spectrophotometrically at λ = 405 nm. Protein concentration was determined using 
the BCA protein assay [89]. 
 
Statistical analysis 
Data represented as mean values plus or minus the standard error, unless otherwise 
noted. Two-way ANOVA with Tukey’s multiple comparison test was employed for 
statistical comparison between experimental groups. A p value less than 0.05 was selected 
prior to the study to determine statistical differences between groups. 
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D. RESULTS AND DISCUSSION 
Liver Toxicity and Cell Proliferation Effects of WY-14,643 in Mouse Liver 
To determine if Kupffer cells are involved in chronic effects of peroxisome 
proliferators in liver, NADPH oxidase-deficient (p47phox-null) and C57BL/6J wild type mice 
were fed 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (WY-14,643)-containing 
diet (0.1% w/w) for 1 week, 5 weeks or 5 months. In parallel, Pparα-null and SV129 wild 
type mice were also treated for up to 5 months. Over the course of treatment there was a 
significant decline in body weight (approximately 20%) in all WY-14,643-treated mice as 
compared to controls, except for Pparα-null mice (Figure 3.1A). This effect was 
accompanied by significant progressive increases in absolute and relative liver weight in all 
WY-14,643-treated groups, except for Pparα-null mice (Figure 3.1B). By 5 months of 
treatment, the liver enlargement was most pronounced in p47phox-null mice. The effect of 
WY-14,643 was much greater in C57BL/6J mice than in SV129 strain. High attrition was 
also observed in WY-14,643-treated mice (Figure 3.1C), particularly those on the C57BL/6J 
background strain.  
Upon necropsy and histopathological assessment, necrotic gross liver lesions (no 
more than 2 mm in diameter) were found in one half of the SV129 wild type mice and all of 
the p47phox-null mice treated with WY-14,643 for 5 months. Overall liver necrosis and 
inflammation scores in these two groups were significantly higher than in control-fed mice or 
C57BL/6J and Pparα-null mice fed WY-14,643 (Figure 3.2E and Appendix 1). Activity of 
serum alanine aminotransferase (ALT), a serum marker of liver injury, was significantly 
elevated in WY-14,643-treated wild type strains and p47phox-nulls, but not Pparα-null mice 
(Table 1) in all time points.  
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Low grade lipid accumulation in hepatocytes was found in both WY-14,643-treated 
wild type strains and p47phox-null mice (Figure 3.2F). Livers from control or WY-14,643-
treated Pparα-null mice showed moderate levels of lipid accumulation (Figure 3.2C and 
Appendix 1). Other groups of mice fed control diet displayed normal liver morphology.  
The selection of the dose of WY-14,643 for this study was based on previous acute, 
sub-chronic and chronic studies in the mouse. While several previous long-term dietary 
feeding studies with peroxisome proliferators in rodents reported relatively high attrition 
rates [21,116,117], we found that the survival of p47phox –null and wild type C57BL/6J mice 
in our study was below 40% with pronounced temporal increases in ALT levels. This 
indicates that 0.1% (w/w) WY-14,643 is higher than a maximal tolerated dose in both SV129 
and C57BL/6J strains. Thus, the long-term carcinogenicity studies conducted in other mouse 
strains with this compound may not be interpretable under the same standards as traditional 
2-year cancer bioassays.  
 The similarities in WY-14,643-induced liver injury across strains and the disparate 
survival of C57BL/6J versus SV129 mice suggest that strain variations in response to WY-
14,643 may not be a result of liver toxicity alone. Several studies reported significant weight 
loss in rodents given peroxisome proliferators chronically [21,116-118]. Excessive energy 
metabolism resulting in a significant reduction in fat stores is thought to be the primary 
contributing factor to this effect of PPARα agonists. Indeed, we also observed that WY-
14,643 "responder" strains (SV129 wild type, C57BL/6J wild type and p47phox-nulls) lost at 
least 20% of the body weight. However, the rate of weight loss between strains was 
remarkably different. C57BL/6J mice had a much higher initial rate of weight loss, a 
response that could be associated with high morbidity/mortality of these mice when given 
 58
WY-14,643. Given the considerable loss of body mass, it is possible that muscle wasting 
[119] was the contributing factor in the premature deaths. 
As expected, we found that WY-14,643 causes remarkable hepatomegaly and induces 
cell proliferation in liver (Figure 3.3A). However, the temporality of WY-14,643-induced 
liver enlargement and cell proliferation patterns observed in this study is not consistent with 
previous reports that peroxisome proliferators cause a rapid up-and-down surge in cell 
proliferation in the first week of treatment [38]. In our study, all WY-14,643 "responder" 
mouse strains exhibited a robust elevation in BrdU labeling in liver for as long as treatment 
continued. While there are notable differences in our experiment and previous reports (e.g., 
rodent species, detection methods, etc.), we argue that the pathophysiological effects of 
peroxisome proliferators in rodent liver, including the robust proliferative response, extends 
beyond the time frame that was traditionally considered. In addition, our findings of 
significant liver injury may suggest that hepatocellular proliferation may be elevated, at least 
in part, due to compensatory liver regeneration.   
 
NADPH oxidase deficiency does not prevent hepatocellular proliferation, but affects the 
decrease in apoptosis caused by WY-14,643 
It was suggested that activation of Kupffer cells and resultant production of oxidants 
and mitogenic cytokines plays a role in acute cell proliferation response caused by 
peroxisome proliferators [65,66]. To determine if Kupffer cell NADPH oxidase is necessary 
for a sustained growth response caused by these agents, changes in liver morphology, BrdU 
incorporation and alterations in protein markers of cell turnover were assessed.  
 59
Histological evaluation of livers from WY-14,643-treated p47phox-null revealed 
significantly hypertrophied hepatocytes, an increase in mitotic bodies and presence of 
binucleate hepatocytes, effects identical to those observed in C57BL/6J wild type mice. 
Furthermore, a significant temporal increase in hepatocellular proliferation was observed at 
all time points with a peak at 5 weeks in both p47phox-null and wild type mice (Figure 3.3A). 
Western blot analysis of 5 month liver tissue was conducted to determine if Kupffer cell 
oxidants are important in cell cycle regulation of proliferation (Table 3.2). WY-14,643-
induced increases in Cyclin B1, Cdk1 and Cdk4 expression were not affected by Kupffer cell 
NADPH oxidase deficiency. However, as previously reported [39], altered expression of 
these proteins caused by peroxisome proliferators was dependent on PPARα. 
Suppression of apoptosis has been suggested as another key mechanism by which 
peroxisome proliferators may affect liver cell turnover and contribute to carcinogenesis. A 
number of studies have argued that reduced apoptosis after exposure to peroxisome 
proliferators is a TNFα-mediated (i.e., Kupffer cell-dependent) response [41,120]. To 
determine if, in fact, a sustained reduction of apoptosis is present during long-term feeding of 
these agents and whether it is dependent upon Kupffer cell NADPH oxidase, expression of 
Caspase 8 and Caspase 9 proteins was assessed. Treatment with WY-14,643 for 5 months led 
to a decrease in expression of Caspase 8 in both wild type strains (Table 3.2). Interestingly, 
this effect was dependent both PPARα and Kupffer cell NADPH oxidase since no reduction 
in Caspase 8 expression in response to WY-14,643 was observed in either knockout strain. 
Levels of Caspase 9, which leads to apoptosis as a result of mitochondrial stress, remained 
unchanged in all WY-14,643-treated animals.  
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 To further assess the mechanism by which WY-14,643 perturbs normal cell turnover 
in mouse liver, NFκB binding activity was measured. This transcription factor is thought to 
be intimately involved in apoptosis and cell proliferation [121]. Exposure to a single dose of 
WY-14,643 leads to rapid activation of NFκB in Kupffer cells and then in hepatocytes [74], 
an effect that was shown to be dependent upon NADPH oxidase [77]. Other studies showed 
that NFκB activation by peroxisome proliferators in rodent liver is sustained [73] and may be 
important for tumor promotion by these agents [122]. Our data shows that sub-chronic 
treatment with WY-14,643 leads to a sustained elevation in NFκB binding activity in liver 
(Figure 3.3B). Furthermore, NFκB activation appears to be dependent on PPARα and is 
unaffected by the lack of NADPH oxidase, further supporting a temporal shift from Kupffer 
cell- to hepatocyte-centric effects of peroxisome proliferators. Given that NFκB activation by 
peroxisome proliferators is thought to be, in part, due to oxidative stress [75], it is possible 
that PPARα-dependent oxidant production in hepatocytes as a result of long-term WY-
14,643 treatment is responsible for the continued induction of NFκB binding observed here. 
 Collectively, while several studies suggested that the acute effects of WY-14,643 in 
rodent liver are mediated through PPARα-independent activation of the Kupffer cell, this 
report shows that this component of the mode of action is short lived and not sustained. 
Indeed, p47phox-null mice responded to sub-chronic treatment with WY-14,643 with the most 
pronounced hepatomegaly, increase in liver cell proliferation, and exhibited upregulation of 
cell cycle proteins, while Pparα-null mice showed no response to treatment, as expected 
[21,116]. The lack of a sustained effect of the Kupffer cell-mediated events suggests that 
activation of PPARα is the primary event responsible not only for the induction of 
peroxisomes, but also for cell proliferation in liver. While there is no evidence that PPARα 
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has a direct affect on transcription of cell cycle-regulating genes [39], there is strong 
evidence for transcriptional regulation by NFκB [121], further supporting the idea that WY-
14,643-induced cell proliferation may be mediated by oxidant-dependent activation of NFκB 
that follows PPARα activation and induction of oxidant-generating enzymes in hepatocytes. 
In addition, a strong PPARα- and NADPH oxidase-dependent suppression of caspase 8, an 
initiator caspase of the death receptor pathway leading to apoptosis [123], was observed. This 
finding suggests that altered regulation of apoptosis by peroxisome proliferators is mediated 
by death receptor pathways that may include multiple signals from the Kupffer cells and 
from within the hepatocyte through a PPARα-mediated pathway. Regardless of the pathway, 
our data on cell proliferation and liver enlargement suggest that suppression of apoptosis may 
not play as large of a role as increased proliferation and induction of oxidant-generating 
peroxisomes. 
 
PPARα, not NADPH oxidase, mediates chronic oxidative DNA damage by WY-14,643 
Peroxisome proliferators induce reactive oxygen species, which are known to cause 
oxidative damage to cellular macromolecules [82,93,124]. Previous studies have 
demonstrated that early increases in reactive oxygen species by peroxisome proliferators 
require Kupffer cell NADPH oxidase [46]. To determine if Kupffer cell NADPH oxidase is 
involved in oxidative DNA damage resulting from long-term peroxisome proliferator 
administration, apurinic/apyrimidinic (AP) sites were measured in DNA from liver of mice 
fed control or WY-14,643-containing diet for 5 months. Chronic treatment with WY-14,643 
caused a two-fold increase in AP sites, a response which required PPARα, but not NADPH 
oxidase (Figure 3.4A). To determine if peroxisomal oxidases are a potential source of 
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prolonged oxidant production contributing to peroxisome proliferator-induced oxidative 
DNA damage, acyl-coA oxidase activity was measured in liver homogenate following 5 
months of WY-14,643-treatment. Activity of this peroxisome proliferation-marker protein 
was increased in a PPARα-dependent manner similar to that observed in peroxisome 
proliferator-induced DNA damage (Figure 3.4B). These findings corroborate previous 
reports that peroxisome proliferators cause oxidative damage [48,82,110] through a 
mechanism that involves oxidants from parenchymal cells.  
Along with altered cell turnover, oxidative DNA damage is another mode of action 
that is considered to be important to peroxisome proliferator-induced carcinogenesis. 
Overproduction of reactive oxygen species from a number of cellular sources can lead to 
oxidative damage of macromolecules in absence of scavenging proteins [42,93]. Induction of 
microsomal and peroxisomal oxidases in hepatocytes and activation of NADPH oxidase in 
Kupffer cells are two potential molecular sources of peroxisome proliferator-induced oxidant 
production, respectively. It was previously shown that dietary administration of WY-14,643 
for up to 1 month led to increased expression of base excision DNA repair genes, a marker of 
oxidative DNA damage in vivo [110]. This effect was shown to be dependent on PPARα, not 
Kupffer cell NADPH oxidase. In the present study we assessed oxidative DNA damage at 5 
months of continuous treatment with WY-14,643 and report that oxidative DNA damage 
persists and continues to be dependent on PPARα, not NADPH oxidase. Taken together with 
the fact that the activity of acyl-coA oxidase, a PPARα target gene, was also observed to be 
elevated following 5 months-long WY-14,643 treatment, these data suggest that peroxisomal 
enzymes, not activated Kupffer cells are the likely source of reactive oxygen species that 
contribute to oxidative DNA damage in the mode of action of peroxisome proliferators. 
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In conclusion, this long term feeding study with a model peroxisome proliferator 
compound WY-14,643 demonstrates that PPARα, not Kupffer cell-derived oxidants are 
important for the key steps critical for carcinogenesis – cell proliferation and oxidative DNA 
damage. While activated Kupffer cells mediate acute effects of these agents on cell 
proliferation and production of oxidants in liver, this pathway appears to not be sustained and 
may play a limited, if any, role in long-term effects of peroxisome proliferators such as 
hepatocarcinogenesis. 
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Figure 3.1. WY-14,643 causes substantial changes in body and liver weight in mice and 
reduced survival of p47phox WT and KO mice. 
 (A) Body weight was recorded on a weekly basis and is plotted for up to 5 months of 
treatment with 0.1% WY-14,643. (B) Liver and body weight were recorded at sacrifice. 
Control liver weights were averaged at 1 week, 5 weeks, and 5 months. Statistical 
significance (p<0.05) is indicated with asterisks (*, different from Control, ** different from 
1 week-treated group, *** different from 5 week-treated group). (C) Animal survival was 
noted every other day.  Kaplan-Meier method was used to plot a time course of survival 
rates.  
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Figure 3.2. Liver histopathology in mice treated for 5 months with WY-14,643. 
 (A)  Normal liver morphology in PPARα +/+ mice on the control diet. (B) Photomicrograph 
of a necro-inflammatory lesion in liver of PPARα +/+ mice treated with WY-14,643 (0.1%). 
Necrotic (n) and inflamed (i) areas are indicated. (C) Steatosis (s) as observed in PPARα -/- 
mice fed WY-14,643 (0.1%). (D) Extensive hepatocellular hypertrophy is evident in p47phox 
+/+ mice treated with WY-14,643 (0.1%).  (E) Regions of necrosis and inflammation in liver 
from p47phox -/- mice fed WY-14,643 (0.1%). (F) High magnification photomicrograph 
shows enlarged hepatocytes, binucleate cells (b) and lipid accumulation in p47phox -/- mice 
fed WY-14,643 (0.1%). (G) High magnification photomicograph showing mitotic cells (m) 
in PPARα +/+ mice fed WY-14,643 (0.1%). 
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Table 3.1. Changes in serum ALT and triglicerides caused by WY-14, 643 in mice 
 Treatment Time course N aALT (U/L) 
aTriglycerides 
(U/L) 
bControl  7        25.1 ± 4.9   101.4 ± 12.3 
1 week 3  109.7 ± 34.9* 55.0 ± 3.2* 
5 weeks 6    572.3 ± 79.7** 55.0 ± 0.0* PPARα +/+ WY-14,643  (0.1%) 5 months 6     760.7 ± 215.3**  29.8 ± 6.0** 
Control  4        21.1 ± 4.1     33.0 ± 0.4 
1 week 3        28.6 ± 16.5             cN/A 
5 weeks 3        12.0 ± 1.7 131.7 ± 24.1* PPARα -/- WY-14,643  (0.1%) 5 months 5        36.6 ± 6.2  201.8 ± 17.6** 
Control  17        49.6 ± 3.6     69.7 ± 6.6 
1 week 12      105.1 ± 13.5*         cN/A 
5 weeks 7   697.5 ± 89.3** 52.4 ± 10.3 p47
phox +/+ WY-14,643 
 (0.1%) 5 months cN/A cN/A cN/A 
Control  3        27.8 ± 6.7 cN/A 
1 week 3  182.2 ± 51.5* cN/A 
5 weeks 3    1454.0 ± 170.8** 30.5 ± 5.5 p47
phox -/- WY-14,643  
(0.1%) 5 months cN/A cN/A cN/A 
 
 
a Values represented are Mean ±  SEM  
b Control values represent average control across all time points  
c N/A:  data is Not Available 
Asterisks denote statistical significance from control (*), 1 week (**) or 5 weeks (***) at a  
level of  p < 0.05 
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Figure 3.3. Changes in cell replication caused by WY-14,643 are independent of 
NADPH oxidase and may be mediated by NFκB. 
PPARα -/-, p47phox -/- and WT mice were fed a WY-14,643-containing diet (0.1% w/w) for 
up to 5 months. (A) Proliferation was measured by immunohistochemical detection of BrdU 
in liver. Control values were averaged at 1 week, 5 weeks, and 5 months. Statistical 
significance (p<0.05) is indicated with asterisks (*, different from Control, ** different from 
5 months-treated group).  (B) DNA binding activity of NFκB was determined using EMSA 
as outlined in “Materials and Methods.” Hela cell nuclear extracts were used as a positive 
control to demonstrate specificity of the NFκB probe. 
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Table 3.2. Effect of WY-14,643 on cell cycle and apoptosis-related protein expression at 
5 months 
 
 Treatment N aCyclin B1 aCdk1 aCdk2 aCdk4 aCaspase 8 aCaspase 9 
Control 2 1.0 ± 0.1 1.0 ± 0.4 1.0 ± 0.8 1.0 ± 0.4 1.0 ± 0.7 1.0 ± 0.2 PPARα +/+ 
WY-14,643  3 32.5 ± 7.9* 10.4 ± 1.4*  0.6 ± 0.1  4.7 ± 0.5*  0.0 ± 0.0*  0.6 ± 0.3 
Control 3 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.7 1.0 ± 0.3  1.0 ± 0.2 PPARα -/- 
WY-14,643  3 1.4 ± 0.2  0.9 ± 0.5 0.9 ± 0.6 1.8 ± 0.6 1.1 ± 0.8 0.9 ± 0.1 
Control 3 1.0 ± 0.5 1.0 ± 0.3 1.0 ± 0.7 1.0 ± 0.6 1.0 ± 0.6 1.0 ± 0.4 
p47phox +/+ 
WY-14,643  3 36.7 ± 6.4*   3.1 ± 0.6* 1.2 ± 0.6   5.7 ± 1.3*   0.1 ± 0.0* 0.7 ± 0.3 
Control 3 1.0 ± 0.1 1.0 ± 0.3 1.0 ± 1.0 1.0 ± 0.8 1.0 ± 0.0 1.0 ± 0.3 
p47phox -/- 
WY-14,643  3 19.3 ± 2.7*   4.1 ± 2.1* 2.3 ± 2.6  4.3 ± 0.2* 1.1 ± 0.5 0.6 ± 0.1 
           
   
a Values represented are Mean ±  SEM and  are normalized to strain-matched control values 
  Asterisk (*) denotes statistical significance from control at a level of p < 0.05 
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Figure 3.4. WY-14,643 induces oxidative stress that is dependent on PPARα, not 
NADPH oxidase 
Mice were administered Control or WY-14,643 (0.1% w/w)-containing diet for 5 months. 
(A) An apurinic/apyrimidinic (AP) site slot blot assay was performed as described in 
“Materials and Methods” to detect oxidative damage of DNA. (B) Activity of peroxisomal 
enzyme, Acyl-CoA oxidase was measured as described in the “Materials and Methods.” 
Statistical significance (p<0.05) is indicated with an asterisk (*, different from Control). 
 
 
 
 
CHAPTER IV 
 
 
 
Gene expression in mouse liver reveals a temporal shift in molecular pathways that 
mediate effects of peroxisome proliferators 
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A. ABSTRACT 
Administration of peroxisome proliferators to rodents causes proliferation of 
peroxisomes, induction of β-oxidation enzymes, hepatocelluar hypertrophy and hyperplasia, 
with chronic exposure ultimately leading to hepatocellular carcinomas. Many of these and 
other pleiotropic responses associated with peroxisome proliferators are nuclear receptor 
mediated events involving peroxisome proliferator activated receptor alpha (PPARα). A 
significant role for nuclear receptor-independent events has also been shown, with clear 
evidence of Kupffer cell-mediated oxidative stress, mitogen production and cell replication 
following acute or sub-acute treatment with peroxisome proliferators in rodents. Recent 
studies have demonstrated that NADPH oxidase is not involved in the sustained proliferative 
effects, oxidant production or DNA damage caused by prolonged PP administration. In an 
effort to determine the timing of this transition from Kupffer cell- to PPARα-modulation of 
peroxisome proliferator effects, gene expression was assessed in liver from PPARα -/-, 
p47phox -/- and corresponding wild-type mice following treatment with 4-Chloro-6-(2,3-
xylidino)-pyrimidynylthioacetic acid (WY-14,643) for 8 hr, 24 hr, 72 hr, 1 wk, or 4 wk. WY-
14,643 -induced gene expression in p47phox-null mouse liver differed substantially from wild-
type mice at acute doses and striking differences in  baseline expression of immune related 
genes were evident. Pathway mapping of genes that respond in a time- and dose-dependent 
manner corroborate existing data demonstrating suppression of immune response, cell death 
and signal transduction and promotion of lipid metabolism, cell cycle and DNA repair by 
peroxisome proliferators. Furthermore, these pathways were by in large dependent on 
PPARα, not NADPH oxidase demonstrating a temporal shift in response to peroxisome 
proliferators from Kupffer cell- to hepatocyte-centric. 
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B. INTRODUCTION 
Peroxisome proliferators (PPs) are a chemical class comprised of a wide range of 
industrial, pharmaceutical and endogenous compounds. These compounds have been the 
subject of debate for several decades because of their carcinogenicity in rats and unknown 
risk to humans, who are likely exposed given the ubiquitous use of such peroxisome 
proliferators as phthalates. Though human health outcomes following long-term exposure to 
peroxisome proliferators are inconclusive, chronic administration of these agents to rats and 
mice leads to development of liver neoplasia by a nongenotoxic mechanism [18]. A number 
of peroxisome proliferartor-induced events leading up to carcinogenesis, including increased 
cell replication, oxidative damage and tumorigenesis itself require activation of nuclear 
receptor peroxisome proliferator activated receptor alpha (PPARα) [21,110]. This receptor is 
largely responsible for lipid metabolism through transcriptional regulation of fatty acid 
oxidation enzymes, apolipoproteins and transporters. Recently PPARα is also involved in 
glucose metabolism and inflammation [125].  Interestingly, among species there are 
substantial structural differences in the DNA binding element, peroxisome proliferator 
response element (PPRE) along with differences in basal PPARα expression, with humans 
exhibiting a tenth of the levels observed in rodents [28]. It is still unclear as to whether the 
divergent  physiological observations among species in response to peroxisome proliferators 
(with mice and rats being the most sensitive) are solely attributed to nuclear receptor-
mediated effects or if these differences are independent of PPARα.  
A wide range of nuclear receptor-independent effects have been attributed to Kupffer 
cell activation by peroxisome proliferators. In vitro studies demonstrate that peroxisome 
proliferators stimulate superoxide and cytokine production by these liver macrophages 
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[66,76,77]. Studies performed in vivo with NADPH oxidase inhibitors and Kupffer cell 
inactivators corroborate that reactive oxygen species production following peroxisome 
proliferator treatment is derived from Kupffer cells, and that these oxidants are directly 
involved in signaling of mitogens which may contribute to proliferative responses [65,77]. 
Furthermore, studies using NADPH oxidase deficient mice (p47phox-null) or PPARα –null 
mice demonstrated that acute oxidant production is derived from Kupffer cells, and not  
PPARα-mediated parenchymal sources [46]. Though key steps (enzyme induction, enhanced 
oxidant production and oxidative DNA damage, increased cell proliferation and suppression 
of apoptosis) in the mode of action of these compounds have repeatedly demonstrated with 
various peroxisome proliferator compounds, insight into the molecular mechanisms 
responsible for these events is still lacking. Understanding the role of receptor-independent 
events in the mode of action of peroxisome proliferators and its relevance to humans is a 
necessary step in predicting human health risk of cancer by these agents.  
Microarray technology has served as a valuable tool for gathering mechanistic 
information regarding toxicants’ molecular targets and temporal progression of toxicity 
leading to a specific disease state, both of which are important for chemical risk assessment. 
Genomic studies investigating the effects of peroxisome proliferators in rodent liver have 
largely supported phenotypic findings from traditional assays.  In an effort to fill the gap in 
knowledge with regards to the temporal relationship between peroxisome proliferator-
modulated effects and molecular mediators of these effects, gene expression analysis was 
conducted in liver from acute, sub-acute and sub-chronically treated p47phox-null, PPARα- 
null and wild type mice with potent peroxisome proliferator, 4-Chloro-6-(2,3-xylidino)-
pyrimidynylthioacetic acid (WY-14,643). We hypothesize that NADPH oxidase-dependent 
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genes which are relevant to the mechanism of hepatocarcinogenic action of peroxisome 
proliferators will respond to acute WY-14,643 treatment, but induction of many of these 
genes will diminish with sub-chronic WY-14,643 treatment. Furthermore, we expect that a 
strong PPARα-specific gene signature will be evident.  
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C. MATERIALS AND METHODS 
Animals, Diet and Tissue Collection 
p47phox-null male mice (C57BL/6J background; [85]), PPARα-null male mice (SV129 
background; [33]), and corresponding wild type counterparts (6-8 weeks of age at the 
beginning of treatment) were used in these experiments. All animals used for this study were 
housed in sterilized cages in a facility with a 12-hr night/day cycle. Temperature and relative 
humidity were held at 22 ± 2°C and 50 ± 5%, respectively. The UNC Division of Laboratory 
Animal Medicine maintains these animal facilities, and veterinarians were always available 
to ensure animal health. All animals were given humane care in compliance with NIH and 
institutional guidelines and studies were performed according to protocols approved by the 
appropriate institutional review board. Prior to experiments, animals were maintained on 
standard lab chow diet and purified water ad libitum. 4-Chloro-6-(2,3-xylidino)-
pyrimidynylthioacetic acid (WY-14,643) was obtained from Aldrich (Milwaukee, WI). Acute 
doses were administered by a single oral gavage of 0 (control), 5 or 50 mg/kg of WY-14,643 
in olive oil. Mice (n=3) were sacrificed either 8 hr, 24 hr, or 72 hr post dosing.  Sub-chronic 
doses of WY-14,643 were administered in the diet ad libitum. NIH-07 was used as the base 
for the powdered diet containing either 0% (control), 0.005 % w/w or 0.05% w/w of WY-
14,643. Mice (n=3) were sacrificed after either 1 week or 4 weeks of dietary treatment. 
Animals had free access to water throughout the study and the health status of the animals 
was monitored every other day.  At sacrifice, mice were anesthetized with pentobarbital (100 
mg/kg) and following exsanguination, livers were removed and weighed. A section from the 
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left lateral lobe was fixed in 10% formalin. The remaining tissue was placed in an eppendorf 
tube and snap frozen in liquid nitrogen. These samples were stored at -80ºC until assayed. 
 
RNA Isolation 
While frozen a small fragment (approximately 10 - 30 mg) was removed for each 
sample  and homogenized for 30 sec in 600 µl RLT buffer (Qiagen, Valencia, CA) containing 
1 % β-mercaptoethanol.  The lysate was centrifuged for 3 min at 13000 rpm.  From the 
resulting supernatant, total RNA was isolated using an RNeasy kit (Qiagen) as per the 
manufacturer’s protocol.  Total RNA integrity and quantification were assessed using RNA 
6000 nano assay LabChips® (Agilent Technologies, Santa Clara, CA) and analysed on a 
2100 Bioanalyzer (Agilent Technologies) as per the manufacturer’s protocol.  
 
cDNA Preparation and Microarray Hybridization 
Preparation of cDNA and labeling was performed using reagents from the low RNA 
input fluorescent linear amplification kit (Agilent Technologies) based on modified version 
of the manufacturer’s protocol. A pooled (kidney, spleen, lung, brain, and liver) RNA sample 
(Cogenics, RTP, NC ) derived from equal amounts of RNA from each of the single organ 
RNA pools was used as a reference and prepared in parallel to the samples of interest  [126].  
Total RNA (2.5 µg) was brought to a volume of 4.5 µl with Rnase-free water and incubated 
for 10 min at 65°C in an eppendorf tube with the cap open so that residual ethanol (from 
RNA isolation) could evaporate. A T7 promoter primer (2.5 µl) was added to the mixture and 
allowed to incubate again for 10 min at 65°C, followed by cooling at 4°C for 5 min. To 
reverse transcribe cDNA from the RNA samples, a cDNA master mix containing the 
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following proportions was prepared:   2 µl of 5X first strand buffer, 1 µl of 0.1M DTT, 0.5 µl 
of 10mM dNTP mix, 0.5 µl of Rnase-free water, 0.8 µl of MMLV reverse transcriptase, and 
0.2 µl of RNaseOUT.  A volume of 5 µl was added to each sample, which was gently mixed 
and allowed to incubate for 2 hrs at 40°C, then 15 min at 65°C and cooled to 4°C for 5 min. 
Next, preparation of fluorescent cRNA synthesis involved addition of 1 µl of Cyanine 3-CTP 
(Cy3) (Perkin Elmer, Wellesley, MA) to the pooled reference sample and cyanine 5-CTP 
(Cy5) to the experimental samples. A transcription master mix was prepared by using the 
following proportion of reagents: 7.85 µl of RNase-free water, 10 µl of 4X transcription 
buffer, 3 µl of 0.1 M DTT, 4 µl of NTP mix, 3.2 µl of PEG, 0.25 µl of RNaseOUT, 0.3 µl of 
inorganic pyrophosphatase, and 0.8 µl of T7 RNA polymerase. To each cDNA sample, 29 µl 
of transcription master mix was added. Samples were mixed gently, followed by 2 hr 
incubation in the dark at 40°C and cooling at for 1 -30 min at 4°C. Finally, unincorporated 
dye-labeled nucleotides were removed from cRNA samples. The entire cRNA sample, along 
with 500 µl of PB buffer and 60 µl of RNase water was added to a spin column from a PCR 
Purificaiton kit (Qiagen), mixed and spun for 15 sec at 10,000 rpm. After discarding the 
flow-through, the column was washed with 500 µl of PE buffer and centrifuged for 15 sec at 
10,000 rpm. The step was repeated using 300ul of PE buffer and centrifuging for 2 min.  
Finally the cRNA was eluted into a new tube by adding 50 µl of EB buffer and spinning for 1 
minute. This step was repeated to produce a final volume of 100 µl. The concentration of the 
purified cRNA samples was then measured.  
A hybridization mixture was prepared by adding 2 µg of Cy-3-labeled reference 
cRNA with 2 µg of Cy-5 labeled cRNA for an experimental sample, 200 µl of Rnase-free 
water, 8  µl of fragmentation buffer and 10 µl of 100x control targets to a fresh tube.  Each 
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sample mixture was incubated for 30 min in the dark at 60°C before hybridizing (overnight 
for at least 17 hr) onto Agilent G4121A microarrays (Agilent Technologies) in a pre-heated 
oven at 60°C. Slides were washed in a solution containing 2X SSC/0.005% TritonX-102 
followed by 0.1X SSC for 10 min each.  Finally each slide was dipped into a 2:1 stabilization 
solution-acetonitrile solution for 10 seconds and stored in a dark box before scanning shortly 
after.  
 
Microarray Data Analysis 
 Data was extracted from arrays using Agilent Feature Extraction 6.0 Software. Data 
was initially represented as log2 (Cy5/Cy3). Array quality was assessed by Feature Extraction 
software and genes with fewer than 70% present data across all arrays were excluded from 
further analysis. A total of 16,030 probes passed this data quality filter. Removal of control 
oligos, and RIKENs, for which little or no functional data was available reduced the list to 
11,421 genes. These transcripts comprised our working data set. LOWESS normalization 
was performed to eliminate dye bias. A second normalization was performed to correct for 
basal differences in gene expression between SV129 and C57BL/6J mice or between wild-
type (WT) and knockout (KO) mice on both backgrounds. For a given gene, the Cy5/Cy3 
ratios were divided by the average Cy5/Cy3 ratio for their time-matched controls. Missing 
data points were calculated using K-nearest neighbor imputation method [127].  Average-
linkage, hierarchical clustering was performed using Cluster software on median centered (by 
genes) data and visualization was facilitated by Treeview [128]. 
 Differentially expressed genes were identified using either Significance Analysis of 
Microarrays  (SAM) or EDGE software [129,130]. SAM was performed in cases where 
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statistical significance across only one variable (time, strain or dose) was being assessed. 
EDGE was preferred for identifying differentially expressed genes across two or more 
variables (i.e. time and dose). EDGE employs a spline –based statistic, which fits data to a 
curve representing the null hypothesis (no statistical difference in expression) and a curve 
representing the alternative hypothesis (differential expression) between two groups of 
interest. A statistic is calculated based on the goodness of fit of the expression data for a 
given gene to these two curves. The spline-based approach provides substantially more 
power compared to t- and F-statistics for multivariate analysis, and is well suited for 
timecourse array studies [131]. Q-values, which represent the false discover rate (FDR) of 
less than 0.05 for SAM and EDGE were selected as thresholds for differential expression. 
Once the list of significant genes was generated by EDGE, a t-statistic was calculated for 
each gene at each strain/time combination to determine statistical difference between high 
dose and control expression. For each strain/time combination, a list of differentially 
expressed genes (P<0.05) was submitted for functional analysis. 
 
Functional Analysis of Significant Genes 
EASE , GOMiner, or High-Throughput GOMiner were used to determine biological 
function of differentially expressed genes, in the context of Gene Onotology (GO) [132,133]. 
EASE or GOMiner was preferred for pathway analysis of genes identified in two class SAM 
comparisons. An EASE score or P value < 0.05 was selected as the cutoff for statistical 
significance EASE and GOMiner, respectively.  High-Throughput GOMiner is designed to 
facilitate pathway mapping in cases when several gene lists are to be analyzed. High-
Throughput GOMiner was used for pathway analysis of significant genes lists generated 
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from EDGE timecourse analysis. A Q-value, representative of the FDR, less than 0.05 and 
P<0.05 were the basis for statistical significance from this analysis. Finally, gene networks 
were prepared with PathwayStudio® 4.0 software (Ariadne Genomics, Rockville, MD) 
[134]. The software uses Medscan natural language processing to gather information from all 
abstracts on PubMed and other public data sources, which is extracted to assemble molecular 
networks.  
 
RT-PCR 
Real-time PCR assays were performed using Taqman ® (Applied Biosystems) low 
density arrays to probe over 300 genes of interest (Appendix 2).  RNA samples from animals 
treated with Control or WY-14,643-containing diet for 4 weeks were used for this analysis. 
Preparation of cDNA and PCR were performed according to the manufacturer’s protocol. 
Quantification of data involved determining calculating 2∆∆CT value. The ∆Ct value for all 
genes were calculated relative to the average Ct value for four GAPDH probes) The ∆∆Ct 
values were calculated using WY-14,643 ∆Ct values relative to mean ∆Ct values for strain-
matched controls. 
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D. RESULTS AND DISCUSSION 
Inherent differences in gene expression between p47phox WT and KO mice  
The aim of this study was to investigate WY-14,643-induced temporal changes in 
gene expression for nuclear receptor-mediated and –independent pathways that may be 
important to the mechanism of action of peroxisome proliferators. In particular, differences 
between gene expression modulation by WY-14,643 in p47phox – and PPARα-null mice were 
to be evaluated.  First, gene expression in control-fed wild-type (WT) and knock-out (KO) 
mice was compared. This analysis was performed with the expectation that identifying 
baseline differences in WT and KO mice may help put chemical-induced gene expression 
changes into perspective. In addition to confirming divergent basal gene expression, putative 
and novel pathways associated with the KO model were revealed. Prior to normalizing with 
time-matched controls, Significance Analysis of Microarrays (SAM) was performed between 
control-fed p47phox WT and KO mice and 2257 differentially expressed genes were identified 
across all time points. Following significance analysis, enriched pathways were identified 
using EASE. Among the several GO biological processes that were differentially expressed 
between p47phox WT and KO mice were immune response, fatty acid metabolism 
(specifically β-oxidation), glucose metabolism and amino acid metabolism (Table 1).  
Divergent expression of genes involved in innate immunity (Figure 4.1A) is not 
surprising given the major role that Kupffer cells play in the liver’s defense response [135]. 
A number of lipid mediators of inflammation exhibited higher basal levels of expression in 
p47phox -/- mice.  These include phosopholipase A2 (Pla2g4a), which plays a role in 
arachidonic acid release and eiconsanoid biosynthesis, prostaglandin endoperoxide synthase 
1 (Ptgs1), also known as cyclooxygenase 1 (Cox1), lipoprotein lipase (Lpl), and NADPH-
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dependent enzyme leukotriene B4 dehydrogenase (Ltb4dh). KO mice also exhibited elevated 
levels of Toll-like receptor 4 (Tlr4), which is a well-known mediator of lipopolysaccharide 
(LPS)-induced inflammation. Complement 3 (C3) and fibronectin 1 (Fn1), which both 
promote phagocytosis were suppressed in p47phox -/- mice. From the heatmap, it appears that 
the p47phox -/- mice initially exhibit suppressed or balanced immune response (8 hr – 1wk), 
that later becomes elevated to comparable or higher levels compared to their wild-type 
counterparts at 4 wk. NADPH oxidase-deficient mice are highly sensitive to  bacterial 
infections that stimulate a robust, chronic inflammatory response [85] that can not be quelled 
in the absence of NADPH oxidase oxidant production. The gradual increase in basal 
expression of inflammatory mediators in these mice after 4 weeks predicts this phenotype. 
Wild-type and p47phox-/- mice also exhibited striking differences in basal gene 
expression for fatty acid metabolism genes, a large number of which are PPARα –regulated 
genes, particularly those encoding peroxisomal and mitochondrial β-oxidation  enzymes 
(Figure 4.1B). Because Kupffer cells do not express PPARα [64], the mechanism of 
suppression of PPARα-reglated genes is unclear. More than one study has connected 
NADPH oxidase to lipid metabolism demonstrating that reactive oxygen species in 
macrophages mediate low density lipoprotein (LDL) oxidation [136,137]. The oxidized LDL 
metabolites are PPARα active and can promote transcription of PPARα target genes. Based 
on this proposed mechanism of induction of PPARα by macrophages, NADPH oxidase-
deficient mice would generate fewer PPARα-active metabolites, and exhibit lower basal 
mRNA levels of PPARα –target genes compared to WT mice, as is observed. 
Interestingly, the reduced expression of fatty acid metabolism genes and induction of 
immune response in NADPH oxidase-deficient mice may have fewer implications for 
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chronic effects of PPARα-ligands than one would expect. For example, reduced basal mRNA 
levels of PPARα target genes in p47phox -/- mice may not result in reduced protein expression 
or enzyme activity, as previous studies have shown control levels of  PPARα protein and 
activity of PPARα-regulated enzyme acyl-coA oxidase (ACO) to be comparable in p47phox  
WT and KO mice. Similarly, WY-14,463-induced enzyme activity was comparable int WT 
and KO mice as well [77,138]. Also, peroxisome proliferator-induced suppression of immune 
response still occurs (see below), despite the elevated expression of defense-related genes in 
control-fed KO mice at 4 wk. 
Basal gene expression in PPARα WT and KO mice was also evaluated. Over 850 
genes showed differential expression, with the predominant pathways distinguishing WT 
from KO mice being fatty acid metabolism, RNA splicing and protein-ER targeting. The 
disparate baseline gene expression between WT and KO mice was the motivation for time-
matched control normalizations (as described in “Materials and Methods”) that was 
performed on all subsequently discussed data. 
 
WY-14,643-induced differences in gene expression between p47phox WT and KO mice 
Using toxicogenomics to validate the role of Kupffer cells as an important mediator 
of early response to peroxisome proliferators, acute and sub-chronic changes in gene 
expression were assessed. In particular, genes that demonstrated an early WY-14,643-
induced change in expression in WT, but not KO were identified (Figure 4.2). Within this set 
of genes which exhibit an early dependence on NADPH oxidase, four classifications were 
made: (A) WY-14,643- up-regulated or (C) down-regulated genes which are not modulated 
by NADPH oxidase at later time points and (B) WY-14,643-up-regulated or (D) down-
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regulated genes which still appear to be modulated by NADPH oxidase following continued 
treatment. Pathway mapping of genes from each classification, using GOMiner was 
performed. Gene set A  was enriched with transcripts involved in cell division, which is 
supported by numerous studies in which DNA synthesis or cell proliferation in response to 
peroxisome proliferators is abrogated as a result of inactivation of NADPH oxidase or 
Kupffer cells [77,139]  Also, induction of cell division at later time points, independent of 
NADPH oxidase supports the elevated cell proliferation observed in other studies conducted 
in our lab (unpublished data). Within gene set B, an increase in defense response, immune 
cell activation and endocytosis are acute responses to WY-14,643 that diminish with long-
term treatment. This gene expression signature is supported by Kupffer cell activation by 
peroxisome proliferators and increased phagocytosis by these cells  [63]. The link between 
Kupffer cells and pathways identified in gene sets C and D is less clear, though several 
studies have reported suppression of amino acid metabolism by peroxisome proliferator 
[140]. 
 
Temporal changes in gene expression reveal a robust sub-chronic signature for WY-
14,643 treatment  
To evaluate the timing of PPARα and Kupffer cell-mediated events, a time course of 
gene expression in WY-14,643-fed mice was performed on array data from each WT or KO 
mouse strain separately using EDGE software.   EDGE analysis of arrays from p47phox +/+ 
mice produced the largest set of differentially expressed genes, with over 1200 time- and 
dose dependent transcripts observed. Hierarchical clustering of these significant genes in all 
strains shows the time- and dose-dependent expression (Figure 4.3). As expected, the timing 
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of gene induction appears to be different among all strains, with a uniformly robust response 
with 1 or 4 wk of continued WY-14,643 treatment. Also, most of these genes appear to be 
PPARα dependent, as little to no WY-14,643-induced change in expression occurs in PPARα 
-/- null mice. Pathway analysis of the significant genes lists was performed using High-
Throughput GOMiner.  Many of the biological processes identified are known to be 
perturbed by peroxisome proliferators (Figure 4.4). 
 Among the processes that are down-regulated by WY-14,643 treatment are immune 
response, cytolysis, electron transport and signal transduction.  Up-regulation of pathways 
traditionally associated with peroxisome proliferators, including lipid metabolism, cell 
division, and response to endogenous stimulus (DNA repair) was also observed. By in large, 
sub-chronic treatment resulted in the most substantial induction of biological processes that 
may be relevant to the carcinogenicity of peroxisome proliferators. As evident in Figure 4.4, 
a robust signature for all of these pathways is observed at 1 wk and/or 4 wk, suggesting that 
the acute changes, even in peroxisome proliferator-induced cell proliferation, which has 
historically been considered an acute/sub-acute occurrence, may be less significant to the 
long-term effects of these compounds.  Only acyl-coA metabolism (and its GO Term 
ancestors) exhibits a strong acute response that is sustained with continued feeding. 
Interestingly, temporal pathway analysis reveals an early PPARα-independent cell replication 
signature (see below), which is likely not relevant to the mechanism of action given the 
abrogated proliferative and tumorigenic response in PPARα-null mice. Many of the gene 
expression changes observed at 4 wk were confirmed using RT-PCR (Appendix 3), in which 
increased expression of genes related to fatty acid metabolism, DNA repair, and ubiquitin-
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dependent protein catabolism was observed and transcript levels for genes involved in signal 
transduction were down. 
 
Gene expression profiling reveals early PPARα-mediated immunosuppression by          
WY-14,643 
In concordance with other studies, gene expression profiles reveal 
immunosuppression by WY-14,643 in a manner that is dependent on PPARα  (Figure 4.5) 
[141-143]. Furthermore we show that the earliest onset of altered immune response occurs 24 
hrs post-dosing with WY-14,643 (Figure 4.4). In particular, our results corroborate previous 
reports demonstrating decreased complement activation. We observed reduced transcript 
levels of complement 1 (C1), C2, C5, C8,  C9 and serine protease mannan-binding lectin 
serine peptidase (Masp1) [144-146]. In addition to serving as important mediators of innate 
and adaptive immune response, complements play a major role in cell death by opsonizing 
apoptotic cells which are later cleared by phagocytes [147].  As a result, suppression of 
complement pathways would likely lead to anti-apoptotic effects, which are considered to be 
an important mode of action in peroxisome proliferator-induced carcinogenesis.  
Altered expression was observed for transcripts encoding cytokines, such as tumor 
necrosis factor (TNF) and interleukin 1 (IL1) and transcription factors that are regulated by 
or involved in regulation of cytokine release, including  necrosis factor kappa B (NFκB), 
E74-like factor 1 (ELF1),  nuclear factor of activated T-cells 5 (NFAT5) , and interferon 
regulator factor 2 (IRF2). Cytokines in the liver, which are mainly produced by Kupffer cells 
serve as important mediators of inflammatory response, but also prime cells to proliferate or 
undergo apoptosis [148]. There is conflicting evidence with regards to the effects of 
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peroxisome proliferators on cytokine production, and their importance to 
hepatocarcinogenesis. While  a number  of studies, have shown that cytokines play a critical 
role in cell proliferation and apoptosis by peroxisome proliferators [41,67,120,149,150], 
others have refuted the that cytokines are a requisite for altered cell turnover by peroxisome 
proliferators [151-153,153]. Evidence of a role for NFκB, a transcription factor which both 
modulates and is modulated by TNFα and other cytokines is slightly more consistent with 
many studies demonstrating PPARα- and/or reactive oxygen species (ROS)-mediated 
induction of NFκB [73-75,122,154] and fewer reports of PPARα-mediated inhibition of 
NFκB [155]. Gene expression in this study would support the latter, but we have recently 
observed (data not published) elevations in NFκB-DNA binding following 5 months of WY-
14,643 treatment that was PPARα-dependent. It should be noted that NFκB expression is not 
exlusive to Kupffer cells, though it has been shown to be preferentially activated in Kupffer 
cells compared to hepatocytes following acute peroxisome proliferator treatment [74]. It is 
very likely that as Kupffer cell-mediated effects diminish, ROS from hepatocytes mediate 
peroxisome proliferator-induced NFκB activation [156]. 
In general the mechanism by which peroxisome proliferators elicit 
immunosuppression is not well understood.  It has been suggested that the anti-inflammatory 
effects of peroxisome proliferators are mediated through PPARα-dependent regulation of 
NFκB inhibitory protein, inhibitory kappa B alpha (IκBα), also known as nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor α (NFKBIA) [157]. Two other 
hypotheses link immune response with lipid metabolism, one of which involves activation of 
PPARα by leukotriene B4 (LTB4) and subsequent clearance of the pro-inflammatory agent 
through metabolism resulting, in a negative-feedback loop that regulates inflammation [141]. 
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The evidence supporting this hypothesis is week, as LTB4 metabolism is not increased as a 
result of PPARα activation. Another theory suggests that peroxisome proliferators modulate 
immune response by modulating serum lipids. WY-14,643 treatment causes a decrease in 
serum lipids, thus altering the proportion of energy from fatty acids to peripheral tissues that 
parcipate in the immune response (i.e., spleen, lymphatic tissue).  NADPH oxidase 
deficiency may render mice more susceptible to a reduction in defense response caused by 
WY-14,643, especially considering their inherent immunocompromised state. Based on gene 
expression from this study, we may conclude that Kupffer cell activation by peroxisome 
proliferators occurs very early (8hr) and diminishes or is overshadowed by a strong PPARα-
mediated suppression of other immune-related responses shortly after (24 hr).  
    
WY-14,643-induced PPARα-independent gene expression may be mediated by other 
PPARs 
 A role for Kupffer cells in induction of cell replication by peroxisome proliferators 
has been demonstrated, with absence of Kupffer cells, Kupffer cell-derived oxidants or 
cytokines resulting in abrogation of cell proliferation [67,71,77]. It is hypothesized that 
mitogenic cytokines engage in cross-talk with hepatocytes to maximally induce PPARα-
mediated cell proliferation.  Also, it is widely known that PPARα activation is required for 
peroxisome proliferator-induced cell proliferation in vivo [21].  However, transcriptional 
regulation of cell cycle regulatory genes by PPARα has not yet been verified. To investigate 
the possibility of cell cycle regulation by mitogens or by PPARα, the PPARα-independent 
gene signature at 24 hr was further assessed, with particular focus on genes contributing to 
the “cell cycle” node (Figure 4.6A). At 24 hr, differential expression of a number of genes 
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largely involved in promoting mitosis was exclusive to PPARα -/- mice. The relevance of 
this signature is unclear given that 1) PPARα -/- mice do not exhibit peroxisome proliferator-
induced hepatocellular proliferation, and 2) induction of these genes is diminished in PPARα 
-/- mice at 4 wks, but elevated in wild type and p47phox -/- mice with continued WY-14,643 
treatment (Figure 4.6B). It has recently been shown that mitogens are required for passage 
through the G2 phase of the cell cycle into M phase [158]. Mitogen-independent progression 
to mitosis is possible, but not before a lengthy cell cycle arrest (~10hr). Given the suppressed 
state of the immune response in WY-14,643- responders (PPARα +/+ and p47phox +/+ and -/-
), it is possible that reduced mitogen release can explain the less robust cell cycle signature at 
early time points.  
 EDGE analysis performed on microarray data from PPARα -/- mice revealed a short 
list of genes with time-and does-dependent expression that are involved in a wide range of 
cellular functions (Figure 4.7).  Among these genes was PPARα target cytochrome P450, 
4a14 (Cyp4a14), which exhibited WY-14,643 suppression at 1wk. WY-14,643 treatment 
caused a decrease in integrin beta 1 binding protein (Itgb1bp1) expression and an increase in 
Irf2, which inhibits transcriptional activation of interferon, suggesting that a PPARα-
independent mechanism of immunosuppression by peroxisome proliferators may be 
involved.  D site albumin promoter binding protein (Dbp) is thought to be involved in 
circadian rhythms, which are known to be perturbed by peroxisome proliferators and fatty 
acids. Cyclin-dependent kinase inhibitor 1A (Cdkn1a), also known as p21, which associates 
with p53 to prohibit cell cycle progression, is significantly up-regulated in PPARα -/- mice 
with sub-acute WY-14,643 treatment and is suppressed at later timepoints. Tubulin 2 
(Tubb2), which is also important to cell cycle regulation, particularly mitosis, exhibits a 
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similar pattern of expression as p21.  Modulation of WY-14,643-induced gene expression by 
other PPARs is a possibility, as Tubb2 possesses a response element for both PPARγ and 
PPARδ [159]. Furthermore macrophages express PPARγ at fairly high levels, but not PPARα 
[160]. It was recently shown that PPARα-null on high fat diet exhibit compensatory 
expression of PPARγ expression, with levels 20-fold higher than in wild-type mice [161]. 
Despite the fact that WY-14,643 is a weak activator of PPAR isoforms other than alpha 
[162], the potential for them to modulate effects of peroxisome proliferators, particularly in 
PPARα-null mice should not be ruled out.  
 
Conclusions 
 In this microarray time course study, we have demonstrated that WY-14,643 elicits 
gene expression changes that contribute to a range of altered biological responses. Many of 
the early gene expression changes appear to be Kupffer cell-mediated. Based on our findings, 
modulation of cell replication by Kupffer cell-derived mitogens, independent of PPARα is 
not evident beyond 24 hr. Also Kupffer cell-mediated defense mechanisms are diminished 
early, as WY-14,643 acts a potent immunosuppressant. This effect is largely PPARα-
mediated. Collectively, these data suggest that Kupffer cells do not play a critical role in 
chronic effects of peroxisome proliferators, but are important for early responses to these 
agents. 
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Figure 4.1. Hierarchical clustering reveals divergent expression of genes involved in 
immune response and fatty acid metabolism between p47phox WT and KO mice. 
Prior to performing time-matched control normalization, unpaired two-class SAM analysis 
was conducted to identify differentially expressed genes between p47phox WT and KO mice 
across all time points. Significant genes (FDR <0.05) were submitted to EASE for biological 
pathway analysis. Hierarchical clustering was performed on genes contributing to A) immune 
response or B) fatty acid metabolism, both of which were identified by EASE as being 
enriched processes (EASE score<0.05). 
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Figure 4.2. Early differences in WY-14,643-induced response between p47phox WT and 
KO. 
Comparative t-tests were performed to identify genes in which early WY-induced expression 
is mediated by NADPH oxidase. Genes from various portiond of the heatmap were submitted 
to GOMiner to identify enriched (P<0.05) biological processes. A & C) These genes exhibit 
an early response to WY-14,643 that remains induced with continued treatment, but only the 
initial induction appears to be mediated by NADPH-oxidase.  B & D) These genes exhibit 
only an early response to WY-14,643 that is NAPDH oxidase- mediated.  
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Figure 4.3. Hierarchical clustering of differentially expressed genes based on EDGE 
analysis. 
Using EDGE software, 1294 temporal and dose dependent genes were identified in p47phox 
+/+ mice.  Statistical significance was determined at P<0.05 and a Q (FDR) of 0.05. 
Hierarchical clustering of these genes in all mouse strains was performed using log2 ratios 
that were normalized to time-matched control arrays. 
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Figure 4.4. Temporal GO Pathway mapping of WY-induced biological processes. 
Significant genes from EDGE analysis were submitted to High-Throughput GOMiner to 
identify overrepresented biological processes resulting from WY-14,643 treatment. 
Supervised hierarchical clustering was performed. Heatmap shading reflects the FDR for a 
given pathway, with darker coloring representing statistically significant pathways. The 
pathway ordering reflects Gene Ontology hierarchy. 
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Figure 4.5. Suppression of immune response at 4 wks is dependent on PPARα, not 
NADPH oxidase. 
Diagrams reveal decrease in expression of genes contributing to the “Immune Response” GO 
pathway at 4 wks (shown in Figure 4.4), except in PPARα -/- mice. Interactions among gene 
products include regulation (gray line) and induction of expression (blue line). Networks 
were prepared using Pathway Studio software. Nodes shaded green are down-regulated 
compared to control, red nodes are up-regulated and gray nodes are molecular mediators that 
did not contribute to the GO analysis. No information regarding gene interactions was 
available for those that are not connected with arrows.   
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Figure 4.6. Network of genes associated with cell proliferation demonstrates shift from 
early PPARα-independence to PPARα-dependence after WY-14,643 treatment.  
Diagrams display altered expression of genes contributing to the “Cell cycle” GO pathway 
(shown in Figure 4.4) at A) 24 hrs and B) 4 wks.  Interactions among gene products, such as 
binding (purple line), direct regulation (gray line) or protein modification (green line) are 
represented. Networks were prepared using Pathway Studio software. Nodes shaded green 
are down-regulated compared to control and red nodes are up-regulated. No information was 
available regarding genes that are not connected with arrows.   
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Figure 4.7. Hierarchical clustering of temporal, dose-dependent genes in PPARα-null 
mice that respond to WY-14,643 treatment. 
EDGE analysis on microarray data from PPARα-null mouse liver RNA samples reveals 12 
differentially expressed genes (FDR<0.05) which respond in a dose dependent manner. 
 
 
 
 
 
CHAPTER V 
 
 
 
GENERAL DISCUSSION 
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A. SUMMARY AND CONCLUSIONS 
 The goal of these studies was to investigate the role of Kupffer cells in mediating 
long-term effects of peroxisome proliferators. Previous work has demonstrated an essential 
role for Kupffer cells in early oxidant production, release of mitogens and increased cell 
proliferation by peroxisome proliferators [97]. We show that Kupffer cell-mediated events 
are not sustained, but rather short-lived and thus likely do not play a role in chronic effects of 
peroxisome proliferators in mouse liver.  
 Oxidant generation has been shown to be an important, early response to peroxisome 
proliferator treatment with evidence that ROS contribute to NFκB activation, cytokine 
production and proliferation of liver parenchymal cells [94]. Previous studies show that ROS 
resulting from acute treatment are derived from Kupffer cells, not parenchymal cells. In 
chapter 2, we provide the first evidence by direct in vivo measurements that oxidant 
production is sustained for up to three weeks of peroxisome proliferator treatment [138]. 
Oxidant levels correlated with peroxisome proliferator carcinogenicity, with WY-14,643 
inducing greater POBN-radical adduct generation than DEHP. Using PPARα -null and 
NADPH oxidase-deficient (p47phox –null) mice, the source of prolonged oxidant production 
was identified as being within parenchymal cells, not Kupffer cell. Peroxisomal enzyme, 
ACO was significantly elevated and the presumed source of oxidants in hepatocytes. These 
findings are important because they demonstrate that prolonged oxidant production in 
Kupffer cells is likely not involved in the mechanism of hepatocarcinogenic action of 
peroxisome proliferators. 
 In Chapter 3, we investigated the role of Kupffer cells on key events in the mode of 
hepatocarcinogenic action of peroxisome proliferators: cell proliferation, apoptosis and 
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oxidative DNA damage. With respect to these events, chronic administration of WY-14,643 
had no effect on PPARα -null mice, as expected. In p47phox –null and wild type mice, cell 
proliferation was still significantly elevated, which was far beyond the timeframe that cell 
proliferation has historically been shown to peak [38].  Suppression of apoptosis was 
observed in only wild-type mice, suggesting a role for both PPARα and Kupffer cells in this 
response. Furthermore, events leading to WY-14,643-induced effects on apoptosis were 
related to a TNFα-mediated pathway, as opposed to mitochondrial. Oxidative DNA damage 
by peroxisome proliferators, which has been inconsistently reported, was demonstrated in 
this study following chronic WY-14,643 feeding. Our findings suggest that DNA damage 
results from oxidant producing enzymes within parenchymal cells, not Kupffer cells. This 
study demonstrates that Kupffer cells play a role in the mode of action in rodent 
hepatocarcinogenesis, by contributing to apoptosis suppression, but not induction of cell 
proliferation or oxidative damage by WY-14,643.  
 In chapter 4, gene expression profiling in p47phox –null, PPARα –null, and wild type 
mice confirmed most of the phenotypic responses observed in the first two studies. Up-
regulation of genes involved in cell cycle, lipid metabolism and DNA repair as well as 
suppression of immune response and cell death were most notable following sub-chronic 
WY-14,643 treatment and were largely modulated by PPARα. A comparison of gene 
expression patterns between p47phox +/+ and p47phox -/- mice revealed significant inherent and 
WY-14,643-induced differences, many of which were related to immune response. 
Furthermore, these differences were most notable with acute treatment and diminished over 
time. The strong immunosuppression by WY-14,643 may play a partial role in suppressing 
apoptosis, but the relevance of altered immune response to hepatocarcinogenicity is unclear. 
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The mechanism for acute PPARα –independent up-regulation of cell cycle genes also 
remains unclear, as it did not definitively appear to be a result of mitogenic cytokines from 
Kupffer cells. The results of this study are important, as they demonstrate that gene 
expression can predict sub-chronic WY-14,643-induced phenotypes. 
Collectively, the findings of these studies demonstrate that Kupffer cell activation by 
peroxisome proliferators is an ephemeral event that likely does not contribute to long-term 
effects of these agents. 
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B. SIGNIFICANCE OF THIS STUDY 
 The human health risk of peroxisome proliferators has been debated for several 
decades [10,96,163] Over the years, significant advances in understanding the mechanism of 
hepatocarcinogenicity have been made. PPARα-dependence for increased cell proliferation 
and tumorigenesis [21] was one of the most important findings, with regard to receptor-
mediated effects of these agents. Also investigations into interspecies differences in PPARα 
expression and function have provided valuable insight which helps explain the disparate 
pathophysiological responses between the humans and rodents [28,164]. The discovery of 
nuclear receptor-independent targets of peroxisome proliferators has remained quite 
controversial but a large body of evidence has demonstrated that Kupffer cells mediate many 
acute pleiotropic effects of peroxisome proliferators, helping to make this concept more 
widely accepted [94]. Until now, studies investigating the role for Kupffer cell in chronic 
effects of peroxisome proliferators in mice were lacking. The overall findings of this study, 
that Kupffer cell derived oxidants are not required for long-term effects of peroxisome 
proliferators, helps to fill large gaps in our understanding of the mechanism of action of these 
agents and thus, should improve the human health risk assessment of these agents.  
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C. LIMITATIONS OF THIS STUDY 
There are a number of challenges and limitations in these studies that should be 
brought to light for the reader. The first limitation involves use of knockout mice. The 
knockout mouse model provides a fairly effective way to study a specific mechanism as it 
relates to chemical-induced toxicity or disease. They are favored over use of chemical 
inhibitors, because in many cases chemical inhibitors may have non-specific targets. 
However, knock out mice may be no better because there is a possibility of interference of 
off target genes when backcrossing to produce these mouse lines.  Also, knockout mice may 
overexpress another gene to compensate for the absent target gene. Finally, any disease or 
chronic conditions associated with the absent gene may confound study results. 
The next challenge in interpreting results of these studies relates to our limited focus 
on NADPH oxidase. In addition to NADPH oxidase, inducible nitric oxide synthase (iNOS) 
and mitochondrial enzyme, xanthine oxidase are present in Kupffer cells and generate 
reactive oxygen species upon Kupffer cell activation. Oxidants could act as second 
messengers to signal mitogenic cytokine production, leading to increased cell proliferation. 
In absence of a good animal model studies on the effects of Kupffer cell-associated 
mechanisms remains inconclusive. Kupffer cell inactivation for chronic studies has proven 
unsuccessful, as extended glycine treatment failed to inhibit Kupffer cells beyond 22 weeks 
(Wheeler, et al, unpublished). Understanding that these studies do not take into account other 
ROS generated in the Kupffer cells is important.  
Finally, expanding our time course to include time points before 8 hr and beyond 5 
months may have significantly improved our overall understanding of Kupffer cells as a 
mediator of acute effects of peroxisome proliferators and  their relevance to carcinogenesis.  
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The absence of a stronger cell proliferation signature in microarray data at 8 hr, given the 
historical evidence demonstrating an early peak in cell proliferation and evidence of Kupffer 
cell involvement in peroxisome proliferator-induced cell replication, suggests that 
transcriptional changes contributing to these effects may occur before 8 hr. The premature 
termination of our long-term feeding study and as a result, lack of a cancer endpoint limits 
the conclusiveness of our findings. Other studies providing evidence of reduced tumor 
incidence in absence of Kupffer cell-mediated events, still reported increases in cell 
proliferation [65] as was observed in our studies. For this reason, an 11-month WY-14,643-
feeding study should still be conducted in NADPH oxidase-deficient mice to definitively 
determine the role of Kupffer cells in hepatocarcinogenesis by peroxisome proliferators. In 
fact, given that the traditional cancer bioassays are conducted over 2 years, this should be 
considered for subsequent long-term feeding studies in PPARα and p47phox –null mice.  
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D. FUTURE DIRECTIONS 
 In light of these findings disputing the role of Kupffer cells in chronic effects of 
peroxisome proliferators in rodent liver, the next steps in this area of research should focus 
on established differences between susceptible (rodents) and non-susceptible (human) 
species. Inter-species variability in response to peroxisome proliferator compounds is thought 
to be, at least in part, a result of species differences in expression of PPARα in liver 
parenchymal cells. In an effort to mimic this variability, one could look at genetically-
encoded differences in liver PPARα expression between individuals within a single species, 
such as inbred mouse strains. If, in fact, expression levels of PPARα determine the 
peroxisome proliferator-induced phenotype, than the magnitude of peroxisome proliferator-
induced responses should correlate with expression of PPARα; however, thus far we have 
observed little correlation between basal PPARα expression, WY-14,643-induced expression 
and induction of cell proliferation in liver. Thus, additional research is needed to investigate 
the relationship between PPARα mRNA expression, protein expression and protein-DNA 
binding and peroxisomal induction to determine if these correlate with peroxisome 
proliferator-induced hepatocellular proliferation.  
In addition, humanized mouse models which express the human form of PPARα 
(hPPARα) have also been developed to further study receptor differences between species. It 
has been shown that hPPARα mice exhibit reduced hepatocelluar proliferation and tumor 
incidence compared to mPPARα mice when fed WY-14,643  for up to 44 weeks [165,166]. 
Also, increased gene expression of tumor suppressor, p53 was observed only in WY-14,643-
fed hPPARα mice. Additional experimentation with hPPARα mice and investigations into 
the structural and functional differences between hPPARα and mPPARα may provide 
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additional valuable mechanistic insight for risk assessment of peroxisome proliferators. 
Finally, many preliminary studies investigating species differences in PPREs were conducted 
for only one gene, acyl-coA oxidase. With the recent completion of human and mouse 
genome sequencing, we now have the capability to identify sequence differences in many 
other peroxisome proliferator responsive genes to help further understand species differences 
in response to these agents.  
 
 
 
 
APPENDICES
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Appendix 1. Effect of WY-14,643 on histopathological changes in mouse liver following 
5 months of dietary treatment 
 Treatment N Morphology 
Incidence 
of Non- 
neoplastic 
lesions (%)
aSteatosis 
Index 
aNecrosis 
Index 
aInflammation 
Index 
Control 2 Normal 0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 PPARα +/+ 
WY-14,643(0.1%) 6 Hypertrophy 50 0.0 ± 0.0   2.2 ± 1.2*   4.2 ± 1.5* 
Control 4 Fat deposits 0 22.5 ±  7.2 0.0 ± 0.0 0.0 ± 0.0 PPARα -/- 
WY-14,643 (0.1%) 5 Fat deposits 0 16.1 ± 14.2 0.0 ± 0.0 0.0 ± 0.0 
Control 5 Normal 0 0.1 ± 0.1 0.0 ± 0.0      0.3 ± 0.1 p47phox +/+ 
WY-14,643 (0.1%) 3 Hypertrophy 0 0.1 ± 0.1 0.0 ± 0.0   1.1 ± 0.5* 
Control 5 Normal 0 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.4 p47phox -/- 
WY-14,643 (0.1%) 3 Hypertrophy 100   1.5 ± 0.8*   3.3 ± 1.3*   4.1 ± 1.2* 
 
aValue represents Mean ± SEM 
Asterisk (*) denotes statistical significance from control at a level of p < 0.05 
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Appendix 2. Genes assayed using Low Density RT-PCR arrays  
 
Gene 
Symbol Gene Name Assay ID Context Sequence 
Acox1 acyl-Coenzyme A oxidase 1, palmitoyl Mm00443579_m1 GACGGCCAGGTTCTTGATGAAAATC 
Acox2 acyl-Coenzyme A oxidase 2, branched chain Mm00446408_m1 GCCTGGGGACTTGGGACGGACAGTC 
Acox3 acyl-Coenzyme A oxidase 3, pristanoyl Mm00446122_m1 CCTTCCTGGTGCAGATCCGTGACAC 
Acp6 acid phosphatase 6, lysophosphatidic Mm00480076_m1 GCTGGAGGAGCAGGTGGAGTGGAAC 
Adh1 alcohol dehydrogenase 1 (class I) Mm00507711_m1 AAGTCGCCAAGGTGACCCCAGGCTC 
Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide Mm00478838_m1 TGGAAAACTCCGAAACTTCAAATAC 
Adh5 alcohol dehydrogenase 5 (class III), chi polypeptide Mm00475804_g1 GGGAGACAGCATTCGAACTGTTCTA 
Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide Mm00507750_m1 TTCGGGGAAAAGCATTCGGACTGTC 
Adsl adenylosuccinate lyase Mm00507759_m1 GACAGTGCCAACCGACGGATCTGTT 
Adss2 adenylosuccinate synthetase 2, non muscle Mm00475827_m1 CATACCTCATTTCCCAGCAAACCAA 
Akap8 A kinase (PRKA) anchor protein 8 Mm00502292_m1 CAAGGCTACGGAGGCTATGGGGCAT 
Akt1 thymoma viral proto-oncogene 1 Mm00437443_m1 ACTTCTCAGTGGCACAATGCCAGCT 
Alad aminolevulinate, delta-, dehydratase Mm00476259_m1 CGCAGAGCCGGTGCCGACATCATCA 
Aldh9a1 aldehyde dehydrogenase 9, subfamily A1 Mm00480231_m1 GTTCGAGCCAGCCACCGGCCGAGTG 
Ankhzn ankyrin repeat hooked to zinc finger motif Mm00477515_m1 GAGATAGACTTGTCAGATGCGAATC 
Ap1s1 adaptor protein complex AP-1, sigma 1 Mm00475917_m1 CAAGTACTTCGGCAGCGTATGTGAG 
Ap2a2 adaptor protein complex AP-2, alpha 2 subunit Mm00475953_m1 GCACCAGTGCTGCGTCCACACCTTC 
Ap4s1 adaptor-related protein complex AP-4, sigma 1 Mm00480739_m1 TCCAGCGAACAATGCTCATTCATTG 
Apex1 apurinic/apyrimidinic endonuclease 1 Mm00507805_g1 GAACCCAAGTCGGAGCCAGAGACCA 
Apoa1 apolipoprotein A-I Mm00437569_m1 CCAACAGCTGAACCTGAATCTCCTG 
Areg amphiregulin Mm00437583_m1 CACAGTGCACCTTTGGAAACGATAC 
Arhd ras homolog gene family, member D Mm00455907_m1 GCCTTCCCAGAGAGCTACAGTCCCA 
Arl2 ADP-ribosylation-like 2 Mm00480018_m1 ACTGGTGGAGGAGCGCCTGGCTGGA 
Arl4 ADP-ribosylation-like 4 Mm00431857_m1 GCCCGGGAGCAATCGCGTAGCCCGA 
Arntl aryl hydrocarbon receptor nuclear translocator-like Mm00500226_m1 TGATGCCAAGACTGGACTTCCGGTT 
Arpc3 actin related protein 2/3 complex, subunit 3 (21 kDa) Mm00480116_m1 CCCCTCGCGAGACCAAAGACACGGA 
Atf4 activating transcription factor 4 Mm00515324_m1 TAAGCCATGGCGCTCTTCACGAAAT 
Atp5a1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1 
Mm00431960_m1 TCAGAAGACTGGCACAGCTGAGATG 
Atp6v0d1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit D isoform 1 Mm00442694_m1 GCGAGACGCTCGAGGACTTGAAGCT 
Atp6v1a1 ATPase, H+ transporting, V1 subunit A, isoform 1 Mm00431979_m1 GAGACTTCCCTGAGCTCACCATGGA 
Atp6v1b2 ATPase, H+ transporting, lysosomal 56/58kD, V1 subunit B, isoform 2 Mm00431987_m1 TCCTAGATCATGTGAAGTTTCCCAG 
Atp6v1d ATPase, H+ transporting, lysosomal 34kD, V1 subunit D Mm00445832_m1 TTCCCTTCGCGAATGGCACAGACCA 
Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 Mm00437712_m1 TTGGAAAGAGCCTCACGGAGAGAGC 
AU041707 expressed sequence AU041707 Mm00497622_m1 TTCCTCCTGCCACTCAGGATTGCGC 
Axot axotrophin Mm00480418_m1 CATGCAAATGAACAAGCTGAGTATG 
B2m beta-2 microglobulin Mm00437762_m1 GCTTGTATGCTATCCAGAAAACCCC 
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Gene 
Symbol Gene Name Assay ID Context Sequence 
Bag1 Bcl2-associated athanogene 1 Mm00437768_m1 TCCAGCAGGGTTTTCTGGCTAAGGA 
Bcap31 B-cell receptor-associated protein 31 Mm00478914_m1 CTAAAGAAGGGAGCTGCCGAGGATG 
Bcap37 B-cell receptor-associated protein 37 Mm00476104_m1 GGCTCCAAAGACCTGCAGATGGTGA 
Bing4 BING4 protein Mm00517474_m1 TCTCGAACAGGGAGACACCTGGCTT 
Bmp4 bone morphogenetic protein 4 Mm00432087_m1 GAGTTTCCATCACGAAGAACATCTG 
Boct organic cation transporter Mm00480680_m1 CCTGATGCGCCTGGAGCTGTGCGAC 
Brd2 bromodomain containing 2 Mm00515808_m1 CTCCCCACAAGCTCCCTGGGGAAGG 
Brd7 bromodomain containing 7 Mm00478876_m1 CAATTGCAAAGAAAAGACCCAAGTG 
Btc betacellulin, epidermal growth factor family member Mm00432137_m1 GGTCCTTGCCCTGGGTCTTGCAATT 
Bzrp benzodiazepine receptor, peripheral Mm00437828_m1 GGCAGATGGGCTGGGCCTTGGCCGA 
C1qa complement component 1, q subcomponent, alpha polypeptide Mm00432142_m1 GAGAGGGGAGCCAGGAGCTGCTGGC 
Cacna2d3 calcium channel, voltage dependent, alpha2/delta subunit 3 Mm00486613_m1 TGTACAACAAAGATCCTGCCATTGT 
Calb1 calbindin-28K Mm00486645_m1 AGGAATTGTAGAGTTGGCTCACGTC 
Calm1 calmodulin 1 Mm00486655_m1 GAGCAGATTGCTGAATTCAAGGAAG 
Calu calumenin Mm00482945_m1 GTCGTGCAGGAAACCATGGAGGATA 
Car2 carbonic anhydrase 2 Mm00501572_m1 TCAGGACAATGCAGTGCTGAAAGGA 
Car4 carbonic anhydrase 4 Mm00483021_m1 TCTACTGAAGACTCAGGCTGGTGCT 
Casp3 caspase 3, apoptosis related cysteine protease Mm00438045_m1 GGGGAGCTTGGAACGCTAAGAAAAG 
Casp8ap2 caspase 8 associated protein 2 Mm00516278_m1 GTCCTGCCTCTCCACTTAAAAATAA 
Casp9 caspase 9 Mm00516563_m1 AGGATATTCAGCAGGCAGGATCTGG 
Catnb catenin beta Mm00483033_m1 TTGTAGAAGCTGGTGGGATGCAGGC 
Ccng cyclin G Mm00438084_m1 GTCTAAAATGAAGGTACAGGCGAAG 
Ccs copper chaperone for superoxide dismutase Mm00444148_m1 GGACACTGATCGGCACCGGGGAGAT 
Cd164 CD164 antigen Mm00489798_m1 TGCCCACCGTGCTACCAGAAACCTG 
Cdc25a cell division cycle 25 homolog A (S. cerevisiae) Mm00483162_m1 GCCCGCCCAGCTTCCATCCCAGTCT 
Cdc25b cell division cycle 25 homolog B (S. cerevisiae) Mm00499136_m1 TGGCAGAGCGCACGTTTGAACAGGC 
Cdc25c cell division cycle 25 homolog C (S. cerevisiae) Mm00486874_m1 AAGAAAATGCAGCGTTCCTGCTTCT 
Cdc37 cell division cycle 37 homolog (S. cerevisiae) Mm00489601_m1 TCACCAAGATCAAGACCGCTGACCA 
Cdk5 cyclin-dependent kinase 5 Mm00432437_m1 AGATTGGGGAAGGCACCTATGGAAC 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) Mm00432448_m1 ACCAGCCTGACAGATTTCTATCACT 
Cdkn1b cyclin-dependent kinase inhibitor 1B (P27) Mm00438167_g1 AGGAAGCGACCTGCTGCAGAAGATT 
Cdkn2a cyclin-dependent kinase inhibitor 2A Mm00494449_m1 AAGCACGCCCAGGGCCCTGGAACTT 
Cetn3 centrin 3 Mm00514305_m1 AATGAAGTTGTGACAGACTGGATAC 
Ckmt1 creatine kinase, mitochondrial 1, ubiquitous Mm00438216_m1 ATCCCCCGAGCGCTGAGTACCCAGA 
Ckn1 Cockayne syndrome 1 homolog (human) Mm00518465_m1 GGGACAACACCCTGGTGAACTATGG 
Clcn3 chloride channel 3 Mm00432566_m1 ATTGGCCAAGCAGAGGGCCCTGGAT 
Clcn7 chloride channel 7 Mm00442400_m1 CCTCACAGGGGCAGCGATCTGGGCA 
Clk CDC-like kinase Mm00438249_m1 TTCACACGGGATGAAATTGTTGATA 
Cln2 ceroid-lipofuscinosis, neuronal 2 Mm00487016_m1 AGCTTCCCTGCTTCCAGCCCCTATG 
Clu clusterin Mm00442773_m1 TCCACCGTGACCACCCATTCCTCTG 
Col18a1 procollagen, type XVIII, alpha 1 Mm00487131_m1 CTGGGCCACCAGGGCAATTCCCCAT 
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Symbol Gene Name Assay ID Context Sequence 
Cops5 
COP9 (constitutive photomorphogenic) 
homolog, subunit 5 (Arabidopsis 
thaliana) 
Mm00489065_m1 CGAAACCCTGGACTAAGGATCACCA 
Copz1 coatomer protein complex, subunit zeta 1 Mm00490769_m1 ACCGGGTGGCTTTGAGGGGTGAAGA 
Cpt2 carnitine palmitoyltransferase 2 Mm00487202_m1 ACAGCCTGCCCAGGCTGCCTATCCC 
Cri1 CREBBP/EP300 inhibitory protein 1 Mm00517974_s1 ACCGAAGAGCTCGGTTGTGATGAGA 
Crlz1 charged amino acid rich leucine zipper 1 Mm00491687_s1 CGAGAGTGGGGAGGAGGATGGCGAT 
Csf1 colony stimulating factor 1 (macrophage) Mm00432688_m1 AAAGGATTCTATGCTGGGCACACAG 
Csk c-src tyrosine kinase Mm00432751_m1 GCAGCTGGTGGAGCACTACACCACA 
Ctbp1 C-terminal binding protein 1 Mm00516350_m1 TCATTGGACTAGGTCGTGTGGGCCA 
Ctsh cathepsin H Mm00514455_m1 CACACTCAATGACGAGGCTGCAATG 
Ctsl cathepsin L Mm00515597_m1 GCTTGTCAAGAACAGCTGGGGAAGT 
Cxcl12 chemokine (C-X-C motif) ligand 12 Mm00445552_m1 TGCATCAGTGACGGTAAACCAGTCA 
D7Rp2e DNA segment, Chr 7, Roswell Park 2 complex, expressed Mm00473613_m1 TGGGCTACCAGTGGTTGTCCCCATC 
Dab2 disabled homolog 2 (Drosophila) Mm00517751_m1 AGCTAGTCCGTGTACTTTGTGGGTT 
Dap3 death associated protein 3 Mm00517732_m1 GGGTCCAGAAGTTGGACCCGAGGTG 
Dbnl drebrin-like Mm00516526_m1 CCCGACCGACTGGGCTCTTTTTACC 
Ddb1 damage specific DNA binding protein 1 (127 kDa) Mm00497159_m1 TGCCAGCACCCAGGCCCTGTCCAGC 
Ddx15 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 (RNA helicase A) Mm00492114_m1 AATTGGAAGAAAGGTGGTGGTGTCA 
Ddx25 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 25 Mm00600256_m1 TCGAGGAAACCGAATTCCAAGGGGC 
Ddx27 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 27 Mm00461971_m1 CTCAAGAAGAAGCGGGCAGCCACTA 
Ddx6 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 Mm00619326_m1 ATCTTGTTTGCACTGATCTGTTTAC 
Ddx6 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 Mm00492142_m1 CAATCTTGTTTGCACTGATCTGTTT 
Deaf1 deformed epidermal autoregulatory factor 1 (Drosophila) Mm00516805_m1 TGACATGACTCTGAGTGGCCCTGTC 
Dgka diacylglycerol kinase, alpha (80 kDa) Mm00444048_m1 AGATGGGGAAGAGGTTATGAAGGTG 
Dhh desert hedgehog Mm00432820_g1 GTATCGGTCAAAGCTGATAACTCAC 
Diap1 diaphanous homolog 1 (Drosophila) Mm00492170_m1 GCCCCGGCAGGTCAACAGGAAGGCT 
Dld dihydrolipoamide dehydrogenase Mm00432831_m1 TAGGGGAATTGAAATACCAGAAGTT 
Dnaja2 DnaJ (Hsp40) homolog, subfamily A, member 2 Mm00444898_m1 ACATGATGCATCCACTAAAAGTATC 
Dncic2 dynein, cytoplasmic, intermediate chain 2 Mm00494508_m1 CCGTGGGATCTAGACGAGGACCTAT 
Drpla dentatorubral pallidoluysian atrophy Mm00492256_m1 AAAGACCAAAACCGAGCAGGAGCTC 
Dsc2 desmocollin 2 Mm00516355_m1 ACCCTTGCGATCCTTGCACTTGCCT 
Dtr diphtheria toxin receptor Mm00439307_m1 CTCCCTCTTGCAAATGCCTCCCTGG 
Edr1 early development regulator 1 (homolog of polyhomeotic 1) Mm00492282_m1 TGCAGATCAGGTGCAGAACTTGGCA 
Eed embryonic ectoderm development Mm00469651_m1 GAGACGAAAATGACGATGCTGTCAG 
Egf epidermal growth factor Mm00438696_m1 CCTGCAGCTCGGGTCAGTGCATCTG 
Egfr epidermal growth factor receptor Mm00433023_m1 CCGAGCAGTTGCCCCAAATGTGATC 
Eif3 eukaryotic translation initiation factor 3 Mm00468721_m1 TCTGCAACAGGTGGCACAGATTTAT 
Eif4e eukaryotic translation initiation factor 4E Mm00725633_s1 TGTTGGGCTGCATTCCTGGCTGTCT 
EIG180 ethanol induced gene product EIG180 (Interim) Mm00504676_s1 TGGAAAGAGGTTGGGGTGAGACTCA 
Emb embigin Mm00515881_m1 AAACCGCACAGGTTCCCATTGACGC 
Emd emerin Mm00514704_m1 TACCTTCCATCACCAGGTGCGTGAT 
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Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 Mm00514245_m1 AACAGCAGGACAGCTCCCCTTTCTG 
Epgn epithelial mitogen Mm00504344_m1 TAACAACACCGAAGCTGACTACATA 
Ephx1 epoxide hydrolase 1, microsomal Mm00468752_m1 CAAGATTGAAGGGCTGGACATCCAC 
Eplin epithelial protein lost in neoplasm Mm00517749_m1 AAAACAGCGAAGAAGTTTCAGGCGC 
Erbb2 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
Mm00658541_m1 CTGCACCCACTCATGTGTGGACCTG 
Ercc4 
excision repair cross-complementing 
rodent repair deficiency, 
complementation group 4 
Mm00516619_m1 GCCGAGGAGGAATATTTTATCAATC 
Ereg epiregulin Mm00514794_m1 CTTGACGCTGCTTTGTCTAGGTTCC 
Ets1 E26 avian leukemia oncogene 1, 5 domain Mm00468970_m1 GGCTACACAGGAAGTGGGCCGATCC 
Ext2 exostoses (multiple) 2 Mm00468775_m1 CCAGAGACAGGGCACTGCTGGCTGG 
Fbxw4 f-box and WD-40 domain protein 4 Mm00443559_m1 GGACCTCAACAGTGGGCAGCTGATC 
Fhl1 four and a half LIM domains 1 Mm00515772_m1 TCCTGTGTGAGGTCCCTCCAGCTAT 
Fkbp4 FK506 binding protein 4 (59 kDa) Mm00487391_m1 TTGACCTGGGAAAAGGGGAGGTCAT 
Fnbp4 formin binding protein 4 Mm00490113_m1 AACCCGACAGGTTCTCTTTGTAAAG 
Fnta farnesyltransferase, CAAX box, alpha Mm00514973_m1 ACAGTGTGGCATTTTCGGAGAGTTC 
Fntb farnesyltransferase, CAAX box, beta Mm00521491_m1 TGGACGTAAGGAGTGCATACTGTGC 
Foxm1 forkhead box M1 Mm00514924_m1 CAGGAGAGCTATGCTGGTGGTGAGG 
Frg1 FSHD region gene 1 Mm00516374_m1 TGTCTGACTCCAGAATTGCCCTGAA 
Fzd7 frizzled homolog 7 (Drosophila) Mm00433409_s1 TAGGGAGAGAACTGCTGGGTGGGGG 
Gaa glucosidase, alpha, acid Mm00484581_m1 AGCCGCCTCCACTTCAAGATCAAAG 
Gab1 growth factor receptor bound protein 2-associated protein 1 Mm00491216_m1 TGAAGCGTTATGCGTGGAAGAGAAG 
Gapd glyceraldehyde-3-phosphate dehydrogenase Mm99999915_g1 TGAACGGATTTGGCCGTATTGGGCG 
Gcm1 glial cells missing homolog 1 (Drosophila) Mm00492310_m1 TTTTCCAGTCCAAAGGCGAGCATGA 
Gcm2 glial cells missing homolog 2 (Drosophila) Mm00492312_m1 TGACCCACAGATGCCTCAGGAACCA 
Gcs1 glucosidase 1 Mm00498596_g1 AGCATGGCAGCTACAATGTCTTCTG 
Gng3 guanine nucleotide binding protein (G protein), gamma 3 subunit Mm00494686_g1 CCGGATAAAGGTGTCCAAGGCAGCA 
Gnpat glyceronephosphate O-acyltransferase Mm00464931_m1 CTCCTCTATGCGAAAGACCTCAAAA 
Golga4 golgi autoantigen, golgin subfamily a, 4 Mm00516938_m1 AGCCCCTGCTCAGGCTTCCTCCAGC 
Gpd2 glycerol phosphate dehydrogenase 1, mitochondrial Mm00439082_m1 CACGAGTTTCTGCAGCTGATGAGCG 
Gpx3 glutathione peroxidase 3 Mm00492427_m1 AGAGAAGTCTAAGACAGACTGCCAT 
Gstm5 glutathione S-transferase, mu 5 Mm00515890_m1 CAATTCTAACCACGAAAACCTGAAG 
Gtf2i general transcription factor II I Mm00494826_m1 TGCAAGAAATTTGCCGAGGCCTTGG 
Gtpbp2 GTP binding protein 2 Mm00517163_m1 CTGCCCCCAGAGGCTGAAGATGGAA 
Gus beta-glucuronidase Mm00446953_m1 AGCCGCTACGGGAGTCGGGCCCAGT 
H1f0 H1 histone family, member 0 Mm00515079_s1 CAAGGCCTCCAAACCCAAGAAGGCC 
Hiat1 hippocampus abundant gene transcript 1 Mm00468642_m1 TCAGCCCGTGGTGGTACTTTGCTGT 
Hip2 huntingtin interacting protein 2 Mm00516776_m1 AAGATCAATGGGCAGCAGCAATGAC 
Hnf4 hepatic nuclear factor 4 Mm00433964_m1 GGAGATGCTTCTCGGAGGGTCTGCC 
Hoxa2 homeo box A2 Mm00439361_m1 CGGCCACAAAGAATCCCTGGAAATA 
Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 Mm00479916_m1 GTTTGCAAGGTGACACGCTTGGTGC 
Hspa4 heat shock 70 kDa protein 4 Mm00434038_m1 CGCTGCACGCCGGCATGTGTTTCTT 
Ifrg15 interferon alpha responsive gene, 15 kDa Mm00499068_m1 CCTGGCTGGAAATTGTGTGTGACGC 
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Igf2 insulin-like growth factor 2 Mm00439563_m1 CCCGACCTTCGGCCTTGTGGTACCA 
Igfbp4 insulin-like growth factor binding protein 4 Mm00494922_m1 CTTCCACCCCAAACAGTGTCACCCC 
Il6st interleukin 6 signal transducer Mm00439668_m1 ACACCAAAGTTCGCTCAAGGAGAAA 
Imp4a importin 4a Mm00502820_m1 AGAACAATCCTGAGCAGGTTGTGGA 
Iqgap1 IQ motif containing GTPase activating protein 1 Mm00443860_m1 GTATCCACGCCCTCAGTTTGTACCT 
Irf6 interferon regulatory factor 6 Mm00516797_m1 ACATCAACGGTTCTCCCATGGCGCC 
Itgb7 integrin beta 7 Mm00442916_m1 GGCTGCCCTCTGCCAGGAACAGATT 
Itm2b integral membrane protein 2B Mm00515213_m1 TGGATTGCAAGGACCCGGGTGACGT 
Itm2c integral membrane protein 2C Mm00499081_m1 TCCTTGCTCAGCTGGCCCGAGATAA 
Kcnd2 potassium voltage-gated channel, Shal-related family, member 2 Mm00498065_m1 GAGAAAACCACGAACCATGAGTTTG 
Kcnj9 potassium inwardly-rectifying channel, subfamily J, member 9 Mm00434622_m1 ATTTGAAGCAAAACCAGACCCCGCA 
Khdrbs1 KH domain containing, RNA binding, signal transduction associated 1 Mm00516130_m1 ATGAGAGACAAAGCCAAGGAGGAAG 
Kpna1 karyopherin (importin) alpha 1 Mm00434700_m1 TTCAGACACAGGTAATTTTGAATTG 
Laptm4a lysosomal-associated protein transmembrane 4A Mm00493224_m1 TCTGGATCAGTTGCCTGATTTCCCA 
Lasp1 LIM and SH3 protein 1 Mm00464946_m1 TGGATAAGTACTGGCATAAAGCATG 
Lig1 ligase I, DNA, ATP-dependent Mm00495331_m1 ACGGAGAGTCCCTGGTTCGCCAGCC 
Lig3 ligase III, DNA, ATP-dependent Mm00521933_m1 TTTTCAGCAGCAAAACCCAACAACT 
Limd1 LIM domains containing 1 Mm00522167_m1 GCAGCCTGCAGCAGGAAGTTAAGAG 
Lin7c lin 7 homolog c (C. elegans) Mm00457063_m1 GCAACTGCAAAGGCTACTGTTGCTG 
Lrrfip1 leucine rich repeat (in FLII) interacting protein 1 Mm00521802_m1 AGGCGCAAAGACTGGCGGAGGCCAG 
Lyst lysosomal trafficking regulator Mm00465000_m1 GTGACTCAGCTGGCGGGGGCAGTGA 
Madh4 MAD homolog 4 (Drosophila) Mm00484724_m1 GATGGACGACTTCAGGTGGCTGGTC 
Man1b mannosidase 1, beta Mm00487564_m1 TCAGGAGAGGAAATATTCAAGACTA 
Map2k1 mitogen activated protein kinase kinase 1 Mm00435940_m1 GACCAGCTCGGCCGAGACCAACCTG 
Map2k2 mitogen activated protein kinase kinase 2 Mm00445688_m1 CGCCTCTGAGGCAAACCTGGTGGAC 
Map2k3 mitogen activated protein kinase kinase 3 Mm00435950_m1 AGACCAAAGGAAAATCCAAAAGGAA 
Mark2 MAP/microtubule affinity-regulating kinase 2 Mm00433039_m1 GGGACACGGAGCAGCCCACCTTGGG 
Mark3 MAP/microtubule affinity-regulating kinase 3 Mm00522364_m1 GGTACAGTGACCACGCTGGACCAGC 
Mbd3 methyl-CpG binding domain protein 3 Mm00488961_m1 TGACGACATCAGGAAGCAGGAGGAG 
Mcrs1 microspherule protein 1 Mm00522246_m1 GATGGACAAAGATTCTCAGGGGCTG 
Mfng manic fringe homolog (Drosophila) Mm00434941_m1 CAAAAAACCGCACGAAGCTGGTGCG 
MGC18745 hypothetical protein MGC18745 (Interim) Mm00523039_m1 GCGGCCCGCGGCAATGGCACGAGCA 
Mgmt 0-6-methylguanine-DNA methyltransferase Mm00485014_m1 GAAGCAATCCGGTCCCCATCCTCAT 
Minpp1 multiple inositol polyphosphate histidine phosphatase 1 Mm00487691_m1 CCCGACGTCTCAGATATGGAGTGTG 
Mpg N-methylpurine-DNA glycosylase Mm00447872_m1 CATTTCTGGGACAGGTTCTTGTCCG 
Mpv17 Mpv17 transgene, kidney disease mutant Mm00485133_m1 CCAGGTTCTGACAGCTGGATCACTG 
Mtap4 microtubule-associated protein 4 Mm00485247_m1 TACAGCCAGCAACAGAGCTCTCCAA 
Mttp microsomal triglyceride transfer protein Mm00435015_m1 AAAAATCGGGTGGCTGTGGTGATAA 
Muc1 mucin 1, transmembrane Mm00449604_m1 GAGGAGGTTTCGGCAGGTAATGGCA 
Myd116 myeloid differentiation primary response gene 116 Mm00435119_m1 GACGTGCAGCCCGCCGCCCAGACAC 
Myt1 myelin transcription factor 1 Mm00456190_m1 CTGAGGAGTCAGAGCCAGCAGCACA 
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Naglu alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB) Mm00479175_m1 GCCATCACCAGGGTGTTTCCACAGG 
Nap1l1 nucleosome assembly protein 1-like 1 Mm00450101_m1 AATGGCGATCTGGATGATGATGCTG 
Ncoa1 nuclear receptor coactivator 1 Mm00447958_m1 TGGAGTCCCAGAGCCAGTTTACAGC 
Ncoa2 nuclear receptor coactivator 2 Mm00500749_m1 AAGAGGAAGGCGAAGATTTGCAGTC 
Ncoa3 nuclear receptor coactivator 3 Mm00500775_m1 CAGGACCGAGTTCTCTGGGTTTGCG 
Ndr3 N-myc downstream regulated 3 Mm00443491_m1 CCTCCTTCCCCACAGGGTACCAGTA 
Nfe2l2 nuclear, factor, erythroid derived 2, like 2 Mm00477784_m1 AGTCCCAGCAGGACATGGATTTGAT 
Nid1 nidogen 1 Mm00477827_m1 GTGGATGCAGGCACCCATAGGGCAG 
Ninj1 ninjurin 1 Mm00479014_m1 CCCCCGACGCCTTGCCACCCCGCTG 
Nr1d2 nuclear receptor subfamily 1, group D, member 2 Mm00441730_m1 AGCTGAACGCAGGAGGTGTGATTGC 
Nr1h3 nuclear receptor subfamily 1, group H, member 3 Mm00443454_m1 GCCAAAGCAGGGCTGCAGGTGGAGT 
Nr1i3 nuclear receptor subfamily 1, group I, member 3 Mm00437986_m1 GCTCCAAAGTCGGTTTCTGTATGCA 
Nras neuroblastoma ras oncogene Mm00477878_g1 CACTTTGAAGCTGCACTGATGCCCT 
Nsf N-ethylmaleimide sensitive fusion protein Mm00435390_m1 GTTCAGCTTGCCTCAGCGAAAATGG 
Nsmaf neutral sphingomyelinase (N-SMase) activation associated factor Mm00448040_m1 GATGTCAGCGTCAATACTATCAATT 
Nthl1 nth (endonuclease III)-like 1 (E.coli) Mm00476559_m1 CATATCAGGCATAGCAGTGGACACA 
Nucb2 nucleobindin 2 Mm00450268_m1 CTGAAGATGAGGTGGAGGATCATCC 
Ogg1 8-oxoguanine DNA-glycosylase 1 Mm00501781_m1 TCTGGACAGTCCTTCCGGTGGAAGG 
Orc4l origin recognition complex, subunit 4-like (S. cerevisiae) Mm00457224_m1 GCTTGACTGGGAGAGGATTTGAATT 
Osbpl1a oxysterol binding protein-like 1A Mm00498542_m1 CAAGACCCAGCCCAGAACAAGCCTG 
Osp94 osmotic stress protein 94 kDa Mm00495441_m1 CAGGTGCACGCCGGCCTGTATATCT 
Papss1 3-phosphoadenosine 5-phosphosulfate synthase 1 Mm00442283_m1 TCTTCAGGAACGGGACATCGTCCCT 
Pbx2 pre B-cell leukemia transcription factor 2 Mm00479560_m1 GGCCCAGGCCAAGAAACATGCCCTA 
Pcmt1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 Mm00476600_m1 AACCTCCGCAAGAATGGAATCATCA 
Pcna proliferating cell nuclear antigen Mm00448100_g1 CAACTTGGAATCCCAGAACAGGAGT 
Pcolce procollagen C-proteinase enhancer protein Mm00476608_m1 CACTTCGGGCACTGAGCACCAGTTT 
Pcsk7 proprotein convertase subtilisin/kexin type 7 Mm00476621_m1 ATGCTGCGGAGCATTGTGACCACTG 
Pcyt1a phosphate cytidylyltransferase 1, choline, alpha isoform Mm00447774_m1 GAACTCCGTGTGAGCGGCCTGTGAG 
Pdcd6ip programmed cell death 6 interacting protein Mm00478032_m1 CGCAAGGTTGCAGCACGCAGCAGAA 
Pde8a phosphodiesterase 8A Mm00501020_m1 GCTGCTGGCTTCACACGGAGGTTTA 
Perp p53 apoptosis effector related to Pmp22 Mm00480750_m1 CCTCATGGAGTACGCATGGGGACGA 
Pfkl phosphofructokinase, liver, B-type Mm00435587_m1 GGCGGTGATGCGCAAGGTATGAATG 
Pias1 protein inhibitor of activated STAT 1 Mm00497998_m1 AGCCCACCAGTCTAGCTTCAGACAA 
Pik3ca phosphatidylinositol 3-kinase, catalytic, alpha polypeptide Mm00435669_m1 TTTAAAAATGGCGACGACTTACGGC 
Pl6 PL6 protein Mm00480010_m1 GCGCAGAAGGCAACTAGCCCTAAAG 
Pla2g7 
phospholipase A2 group VII (platelet-
activating factor acetylhydrolase, 
plasma) 
Mm00479105_m1 TCTCGGAGCCTTCAGGACGATTTAT 
Plod3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 Mm00478798_m1 AGATTATGAGGGAGGCGGCTGCCGC 
Pmscl2 polymyositis/scleroderma autoantigen 2 Mm00479342_m1 TCTGCCTCAAGAAATTTGTCAAGCC 
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Podxl podocalyxin-like Mm00449829_m1 AGAGGAAGGACCAGCAACGGCTCAC 
Pold1 polymerase (DNA directed), delta 1, catalytic subunit (125kDa) Mm00448253_m1 CCCTAAAGGTGGACCGCTTCCCTTT 
Pole polymerase (DNA directed), epsilon Mm00448288_m1 TCATGCGCAAAGGAGCTCGCTGGTA 
Polg polymerase (DNA directed), gamma Mm00450527_m1 TCCCCCTCGGCCTGGTATTCCTGGT 
Polg2 polymerase (DNA directed), gamma 2, accessory subunit Mm00450161_m1 CTCTTCTTCACGGTGCCTTGGAGCA 
Polh polymerase (DNA directed), eta (RAD 30 related) Mm00453168_m1 ATCGAAATGATAATGACCGCGTGGC 
Poli polymerase (DNA directed), iota Mm00449480_m1 CGGCGGGCAGCTCGCGGGCAGTTTG 
Polm polymerase (DNA directed), mu Mm00450512_m1 CAGAAAGCAGGGCTCCAATATTACC 
Pon3 paraoxonase 3 Mm00447161_m1 ATTGAGGGCCTCGAGAATGGCTCTG 
Ppara peroxisome proliferator activated receptor alpha Mm00440939_m1 GTGGAGATCGGCCTGGCCTTCTAAA 
Pparbp peroxisome proliferator activated receptor binding protein Mm00501992_m1 AAAGAAGATTCTCCTGGGCTCCTCC 
Pparg peroxisome proliferator activated receptor gamma Mm00440945_m1 CAGTGGAGACCGCCCAGGCTTGCTG 
Ppib peptidylprolyl isomerase B Mm00478295_m1 TCACAGTCAAGGTATACTTTGATTT 
Ppm1g protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma isoform Mm00446988_m1 CTCCATGGAGGATGCTCACAACTGT 
Prim1 DNA primase, p49 subunit Mm00477089_m1 CATCCCAAGACAGGTCGGATTTCTG 
Prkcl protein kinase C, lambda Mm00435769_m1 GAAAAGGAGGCAATGAACACCAGGG 
Prkcsh protein kinase C substrate 80K-H Mm00447244_m1 CTGTGGGAAGAGCAGCAAGCTGCTG 
Procr protein C receptor, endothelial Mm00440992_m1 AACTCCGATGGCTCCCAAAGCCTGC 
Psa puromycin-sensitive aminopeptidase Mm00477144_m1 CATATGGCGGTGAAGACTGTCCTCA 
Psma6 proteasome (prosome, macropain) subunit, alpha type 6 Mm00478827_m1 GAACAGACAGTGGAAACTGCAATTA 
Psma7 proteasome (prosome, macropain) subunit, alpha type 7 Mm00478829_m1 CACCGCGGTTGGTGTTCGAGGAAAG 
Psmb2 proteasome (prosome, macropain) subunit, beta type 2 Mm00449477_m1 GTCTTCGGAGTCGGACCCCATATCA 
Psmd7 proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 Mm00477746_m1 AGTGGAGGAAGTTCATGACGATGGG 
Pte2a peroxisomal acyl-CoA thioesterase 2A Mm00652967_m1 ACCTGCTCAGTCACCCTCAGGTAAC 
Pte2b peroxisomal acyl-CoA thioesterase 2B Mm00506680_m1 ATCCAAAGGTAAAAGGCCCAGACAT 
Pten phosphatase and tensin homolog Mm00477210_m1 GGAACTTGCAATCCTCAGTTTGTGG 
Pter phosphotriesterase related Mm00447265_m1 GTCAGTGGAGCAGCTTACAGATGTC 
Ptprk protein tyrosine phosphatase, receptor type, K Mm00436070_m1 CTGATGAAGATGTGCCCGGGCCTGT 
Pts 6-pyruvoyl-tetrahydropterin synthase Mm00478494_m1 ACCGGCTGCACAGCCCATCTCTGAG 
Pvrl2 poliovirus receptor-related 2 Mm00436144_m1 CTCTGTGCGCTACCCTCCAGAAGTA 
Pxmp2 peroxisomal membrane protein 2, 22 kDa Mm00477269_m1 AAGCAGTCAGCAGCGGCATTTTGTC 
Rab1 RAB1, member RAS oncogene family Mm00485436_g1 CACAACAGCAAAGGAATTTGCAGAT 
Rab10 RAB10, member RAS oncogene family Mm00489481_m1 GACATCCTCCGAAAGACCCCTGTAA 
Rab18 RAB18, member RAS oncogene family Mm00441057_m1 GCAAGTCCAGCCTGCTCCTGAGGTT 
Rab2 RAB2, member RAS oncogene family Mm00445482_m1 CTAATGTAGAGGAGGCATTTATTAA 
Rab6 RAB6, member RAS oncogene family Mm00445868_m1 AGGATAGAACCGTGCGATTGCAATT 
Rabggta Rab geranylgeranyl transferase, a subunit Mm00490374_m1 ACCTGGCTCACAAGGATCTCACAGT 
Rabggtb RAB geranylgeranyl transferase, b subunit Mm00599962_m1 AGACGCGAGAAGTTACCAGATGTGT 
Rad1 RAD1 homolog (S. pombe) Mm00487885_m1 TGACAAGCCCTATTTCAGGTTGTCT 
Rad50 RAD50 homolog (S. cerevisiae) Mm00485504_m1 AGACTCTTGACCAAGCAATTATGAA 
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Ralb v-ral simian leukemia viral oncogene homolog B (ras related) Mm00469677_m1 GTTCAGGGAACAGATTCTCCGAGTC 
Rasa3 RAS p21 protein activator 3 Mm00436272_m1 GCTGCACGCATCTTCGAGTGCCAGG 
Rbbp9 retinoblastoma binding protein 9 Mm00489397_m1 CCATCGCAGCCATGAGGTATGCAGA 
Rbl2 retinoblastoma-like 2 Mm00487954_m1 ATTTTAAAGGCCTGTCCGAGGACTG 
Rce1 Ras and a-factor-converting enzyme 1 homolog (S. cerevisiae) Mm00491708_m1 TTGTCCTGGCCCCTCGTTCTTGGGC 
Rcn2 reticulocalbin 2 Mm00488777_m1 GTTCAGGCAGCTTCATCTAAAGGAT 
Rdx radixin Mm00501337_m1 TGAGTGGCAGCACAAAGCTTTTGCA 
Recc1 replication factor C, 140 kDa Mm00488021_m1 TGCCCACCCAGGCCATCTATGCCAG 
Rfc2 replication factor C (activator 1) 2 (40kD) Mm00451399_m1 CCACTACGAGCTGCCGTGGGTTGAA 
Rfx1 vregulatory factor X, 1 (influences HLA class II expression) Mm00501349_m1 AAGTGCGGAGAAGCCGAGGAAGAGG 
Rnf14 ring finger protein 14 Mm00451391_m1 GCCGGAAGATGGCAGACTTTCTGTA 
Rock1 Rho-associated coiled-coil forming kinase 1 Mm00485745_m1 GGAGACCTTCAAGCACGAATTACAT 
Rps6ka1 ribosomal protein S6 kinase polypeptide 1 Mm00436395_m1 CACACCCAGGGATTCGCCAGGCATC 
Rw1 RW1 protein Mm00502154_m1 TACAGGAACAGCGCTCATCCACTGC 
S100a13 S100 calcium binding protein A13 Mm00477273_m1 TGCCTCATTTGCTCAAGGACGTGGG 
Satb1 special AT-rich sequence binding protein 1 Mm00485916_m1 GGTTCCACGCCTGATTCTGGCAGGT 
Scamp2 secretory carrier membrane protein 2 Mm00452165_m1 TAACTTGGGGACCAGTGGTTGGCTT 
Scd2 stearoyl-Coenzyme A desaturase 2 Mm00485951_g1 CACATACTGCAAGAGATCTCTGGCG 
Sdc1 syndecan 1 Mm00448918_m1 CTCTGGCTCTGGCACAGGTGCTTTG 
Sec61a SEC61, alpha subunit (S. cerevisiae) Mm00489804_m1 AAGCCAGAGAGAAAGATTCAGTTTA 
Selel selectin, endothelial cell, ligand Mm00486029_m1 GCCAACAGGCGCTTCAGACACTGAT 
Sepr selenoprotein R Mm00489121_m1 CACTTCGAGCCAGGTGTCTACGTGT 
Sh3d2b SH3 domain protein 2B Mm00489003_m1 TCTACAAGGCGAGCCAGCTGGTCAG 
Shc1 src homology 2 domain-containing transforming protein C1 Mm00468940_m1 GAGACCCTGGACATGAACAAGCTGA 
Shyc selective hybridizing clone Mm00488194_m1 AAGTATTTCAAGCAGCTGCAGGTGG 
Skd3 suppressor of K+ transport defect 3 Mm00486168_g1 CCGACCCATCTTGAAAGCTCACTTC 
Slc16a1 solute carrier family 16 (monocarboxylic acid transporters), member 1 Mm00436566_m1 TGTTATTGGAGGTCTTGGGCTTGCT 
Slc20a1 solute carrier family 20, member 1 Mm00489378_m1 ATCCTCCGTAAGGCAGATCCGGTTC 
Slc4a1 solute carrier family 4 (anion exchanger), member 1 Mm00441492_m1 GACCCAGAAGCTCTTCCCACAGAGC 
Slc7a8 solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 Mm00444250_m1 TCCTCCCGGCTGTTCTTTGCTGGAG 
Slc9a1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 Mm00444270_m1 CGGGTGCTGGGTGTCCTGGTCCTGA 
Smpd1 sphingomyelin phosphodiesterase 1, acid lysosomal Mm00488318_m1 CACACCCTAAGAATTGGGGGCTTCT 
Soat1 sterol O-acyltransferase 1 Mm00486279_m1 AGAACCACAGAGCCAAAGATCTGAG 
Sorbs1 sorbin and SH3 domain containing 1 Mm00501490_m1 TGAGCCCACAGCAACCTCAAGCCCA 
Sos1 Son of sevenless homolog 1, (Drosophila) Mm00436712_m1 TTCAGATGTGGAGGAACGTGTTCAA 
Sparcl1 SPARC-like 1 (mast9, hevin) Mm00447780_m1 GCCACCTCTCCGCAGATCTAGCCAG 
Sptlc1 serine palmitoyltransferase, long chain base subunit 1 Mm00447343_m1 ACAACATCGTGTCCGGCCCTCCAAC 
Sqle squalene epoxidase Mm00436772_m1 AGCTGGGCCTTGGAGATACAGTAGA 
Src Rous sarcoma oncogene Mm00436783_m1 GAAGGTGGATGTCAGAGAGGGAGAC 
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Star steroidogenic acute regulatory protein Mm00441558_m1 CAGTATTGACCTGAAGGGGTGGCTG 
Stip1 stress-induced phosphoprotein 1 Mm00489584_m1 GGCCAGGCTATGGAGCAGGTGAATG 
Stmn3 stathmin-like 3 Mm00456285_m1 TGGCCAGCACCGTATCTGCCTACAA 
Stx5a syntaxin 5A Mm00502335_m1 CGATTCAGAGGATCGACGAGAATGT 
Stx7 syntaxin 7 Mm00444002_m1 GCAGACTATCAGCGCAAATCCAGGA 
Supt5h suppressor of Ty 5 homolog (S. cerevisiae) Mm00449743_m1 GGCGGAGGAGGCCGAGGTTGAGGAA 
Tacstd2 tumor-associated calcium signal transducer 2 Mm00498401_s1 CAGACCTCGGTGTGCTGGTGCGTAA 
Tceb3 transcription elongation factor B (SIII), polypeptide 3 (110kD) Mm00496800_m1 TCCAGTAGAGCGAAATAGTGAGGCC 
Tcfl4 transcription factor-like 4 Mm00448970_m1 CAACAGCCTGGATCCTGGGCTTTTT 
Tde1 tumor differentially expressed 1 Mm00449549_m1 TCCCTCGCCAGCTGGGTCCCGTGCC 
Tdo2 tryptophan 2,3-dioxygenase Mm00451266_m1 CCAAAATGGCCATGTCAGGGATGAG 
Tex261 testis expressed gene 261 Mm00493609_m1 TCCTGTCATGCGGGCTAGTGGTGGT 
Tgfa transforming growth factor alpha Mm00446231_m1 GCTAGCGCTGGGTATCCTGTTAGCT 
Tgfb1 transforming growth factor, beta 1 Mm00441724_m1 GTGGACCGCAACAACGCCATCTATG 
Tgfb2 transforming growth factor, beta 2 Mm00436952_m1 CACCTCCCCTCCGAAAATGCCATCC 
Tgfbi transforming growth factor, beta induced, 68 kDa Mm00493634_m1 GGTCGCCAGCACGGCCCCAATGTAT 
Th1l TH1-like homolog (Drosophila) Mm00498553_m1 GACGGCGGCCAGCATCAGGAAGATG 
Tjp1 tight junction protein 1 Mm00493699_m1 TCTGAGGGGAAGGCGGATGGTGCTA 
Tnf tumor necrosis factor Mm00443258_m1 AAAGGGATGAGAAGTTCCCAAATGG 
Tnfaip2 tumor necrosis factor, alpha-induced protein 2 Mm00447578_m1 GAACCTCTACCCCAATGATATTCTC 
Tom1 target of myb1 homolog (chicken) Mm00495692_m1 CTCCTGAGCAGATTGGGAAGCTGCG 
Tpp2 tripeptidyl peptidase II Mm00447609_m1 TCCCAAGCCAATAAACTAATCAAGG 
Tra1 tumor rejection antigen gp96 Mm00441926_m1 TCCTGCTGACCTTCGGGTTCGTCAG 
Trap100 thyroid hormone receptor-associated protein 100 kDa Mm00501920_m1 CATTAGTTCCCAGATGGTGTCCTGC 
Trp53 transformation related protein 53 Mm00441964_g1 GGGAGCGCAAAGAGAGCGCTGCCCA 
Tssc4 tumor-suppressing subchromosomal transferable fragment 4 Mm00502351_g1 TAGTGGAGGTGGGACGGGTGTCAGG 
Ttc3 tetratricopeptide repeat domain Mm00493917_m1 CACCTCCAAGTCAGCCTCCAAGACA 
Ttr transthyretin Mm00443267_m1 ATGAATTCGCGGATGTGGTTTTCAC 
Txn2 thioredoxin 2 Mm00444931_m1 ACTTTCATGCACAGTGGTGTGGCCC 
Txnip thioredoxin interacting protein Mm00452393_m1 AGAGCAGCCTACAGGTGAGAACGAG 
Uchl5 ubiquitin carboxyl-terminal esterase L5 Mm00497950_m1 TTTTGCCAAGCAGGTAATTAATAAT 
Ulk2 Unc-51 like kinase 2 (C. elegans) Mm00497023_m1 AGGCACTCCTCAGGTTCTCCAGTGC 
Unc5h3 unc5 homolog (C. elegans) 3 Mm00494093_m1 ACAATGGGAGGATGTTGTGGTGGTT 
Ung uracil-DNA glycosylase Mm00449156_m1 GACATCCGAGATGTGAAGGTTGTCA 
Usf1 upstream transcription factor 1 Mm00447694_m1 GTCGTTCTCGGGCAAGGACTTAGCA 
Usp14 ubiquitin specific protease 14 Mm00458097_m1 CAACCGCTATGGAATTGCCATGTGG 
Usp21 ubiquitin specific protease 21 Mm00450059_m1 TGACAAGATGGCTCACCACACACTG 
Usp4 ubiquitin specific protease 4 (proto-oncogene) Mm00495954_m1 GTTCCCAGTCAGAGCTCTGAACATG 
Usp5 ubiquitin specific protease 5 (isopeptidase T) Mm00496731_m1 CACGCCGGAGTCTGAGGGTGGCCTC 
Vamp8 vesicle-associated membrane protein 8 Mm00450314_m1 TTGGAAGCCACGTCTGAACACTTCA 
Vapb vesicle-associated membrane protein, associated protein B and C Mm00498148_m1 CAAGTTCCGAGGTCCCTTCACTGAT 
Vps29 vacuolar protein sorting 29 (S. pombe) Mm00451139_m1 ACAGGATGTTGGTGTTGGTACTAGG 
Wbp1 WW domain binding protein 1 Mm00497419_m1 GCAACAGCAGCAGAGTCCGGCAGCA 
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Wee1 wee 1 homolog (S. pombe) Mm00494175_m1 ACGAATACTGTAATGGTGGGAGTTT 
Wisp2 WNT1 inducible signaling pathway protein 2 Mm00497471_m1 GTGCTGTGTGCCTCTTCGAAGAGGA 
Xpa xeroderma pigmentosum, complementation group A Mm00457111_m1 ATGAACCAGGGCCCGTCATGGAGTT 
Xpc xeroderma pigmentosum, complementation group C Mm00456378_m1 AGGAGAGCGTTGCGGATGACTTTGA 
Xrcc1 X-ray repair complementing defective repair in Chinese hamster cells 1 Mm00494229_m1 CTGCCCTCCCGGAGGTACCTCATGG 
0610009M14 
Rik RIKEN cDNA 0610009M14 gene Mm00470231_m1 GCGATGACGATAGTGGTTCCGGAAG 
0610040D20 
Rik RIKEN cDNA 0610040D20 gene Mm00480910_m1 GGACCGCCCAACTCGAGAGCATACA 
0710008N11 
Rik RIKEN cDNA 0710008N11 gene Mm00458268_m1 TCGGCCTGCAGTTTCAGGCCTGTCG 
1110021H02 
Rik RIKEN cDNA 1110021H02 gene Mm00502923_m1 AATATCAGTCCCTGATCCGGTATGT 
2610203K23Rik RIKEN cDNA 2610203K23 gene Mm00508088_m1 GAGAGAACGCTGACGGTTCATGAGA 
5830483C08Rik RIKEN cDNA 5830483C08 gene Mm00724022_m1 GAAGCCCCACCTCAGGAACCTATTT 
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Appendix 3. Hierarchical clustering or RT-PCR data demonstrates PPARα-dependence 
of WY-14,643 modulated genes involved in processes similarly identified by microarray 
analysis. 
Over 300 genes were probed using RT-PCR low-density arrays. ∆∆CT quantification was 
performed as described in “Materials and Methods.” Genes that are visually differentially 
expressed in the heatmap were submitted to GOMiner for pathway analysis. 
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